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Abstract 
Therapeutic protein drugs are receiving increasing attention in pharmaceutical industry 
due to the fast development of biotechnology and genomics. Because of their low oral 
and transdermal bioavailabilities, fragility and short half-lives in vivo, novel and effective 
alternatives to deliver protein therapeutics are an important issue for protein therapeutics’ 
application.  
 Biodegradable polymer devices have been utilized as a means to deliver drugs in 
a controlled and less invasive manner. Poly(lactide-co-glycolide) (PLG) and poly(lactic 
acid) (PLA) microparticles such as double-wall/monolithic microspheres and 
microcapsules have been heavily investigated for controlled delivery of small-molecule 
drugs as well as peptides, proteins and DNA. The size distribution of protein-loaded 
biodegradable polymer microparticles is a crucial factor for allowable routes of 
administration. Also, geometric structure of microparticles can influence the resulted 
release profile.  
 In this project, by using the Precision Particle Fabrication (PPF) method, we 
produced uniform double-wall microspheres (DWMS) with a bovine serum albumin 
(BSA)-loaded PLG core and a drug-free PLA shell. Different PLG and PLA molecular 
weight and organic solvent combination to dissolve core and shell polymers (organic 
solvent configuration) were used to produce uniform DWMS with average size around 55 
µm and ~10 µm shell thickness. By studying the in vitro release profiles, intraparticle 
protein distribution and particle morphology, we found using fast extracting shell solvent 
ethyl acetate, lower molecular weight PLG (Mw 4.2 kDa) core and relatively lower 
molecular weight PLA (Mw 43 kDa) shell resulted in spherical double-wall microspheres 
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with higher protein loading, better core entrapment and postponed protein release 
compared to monolithic microsphere controls. Subsequently, using the optimized 
polymer and organic solvent configuration and increasing the shell PLA/core PLG mass 
ratio from 1.09 to 3.04, we were able to fabricate DWMS with drug-free shell thickness 
varied from ~6 to ~14 µm and an extended period of “zero-order” or constant-rate protein 
release was achieved for five months when drug free shell thickness increased to ~14 µm.  
 In addition to uniform double-wall microspheres, we fabricated microcapsules 
comprising a protein-loaded liquid-core (emulsion of aqueous BSA solution and canola 
oil) surrounded by a PLG shell. By increasing PLG shell flow rate from 30 to 50 mL/h 
while keeping liquid-core flow rate constant at 1 mL/h using PPF, uniform liquid-core 
microcapsules with different PLG shell thickness from ~14 to ~19 µm were obtained. 
The release profiles showed pulsatile release of encapsulated protein with thicker PLG 
shell resulting in detained starting time of protein pulsatile release.     
 In summary, PPF was employed to produce uniform biodegradable microparticle 
systems for protein delivery. For double-wall microspheres as well as liquid-core 
microcapsules, organic solvent configuration, polymer molecular weight and particle 
geometric structure such as overall diameter and shell thickness can be crucial factor for 
protein intraparticle distribution, particle degradation/erosion rate, and thus protein 
release profile.  
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Chapter 1. Introduction 
1.1 Current Issues in Delivery of Therapeutic Proteins 
With the fast development in biotechnology and genomics, new macromolecular 
therapeutics such as proteins and DNA are taking place of conventional small-molecule 
drugs in many areas. In particular, proteins possess the most dynamic and diverse 
functions of any macromolecule in the body, catalyzing biochemical reactions, providing 
scaffolding support, and transporting molecules within a cell or from one organ to 
another [1]. In the pharmaceutical and biotechnology industry, therapeutic protein 
production is and will likely continue to be an R&D-intensive sector. At present over 150 
different proteins or peptides have been approved for clinical use by the U.S. Food and 
Drug Administration (FDA), and many more are in development. Experts estimate the 
fast growing global market of therapeutic proteins will reach $141.5 billion by the end of 
2017 [2]. 
 Hundreds of protein therapeutics are currently marketed or undergoing clinical 
trial including monoclonal antibodies, growth factors, soluble receptors, hormones and 
cytokines. The advantages of protein therapeutics over conventional small-molecule 
drugs include: protein drugs have highly specific and complex functions compared to 
simple chemical compounds; since proteins are highly specific, there is less possibility 
for proteins to interfere with normal biological process, thus less adverse effects; protein 
drugs are often well tolerated and are less likely to elicit an immune response; for some 
genetic diseases, protein drugs can provide effective replacement treatment for gene 
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therapy which is still in its infancy; due to the unique form and function of proteins, 
companies are able to obtain far-reaching patent protection for their products [1].  
 Although protein therapeutics have many attractive properties, they also have 
disadvantages that, if unaddressed, will severely limit their acceptance and application. 
These include low oral and transdermal bioavailabilities, fragility and short half-lives in 
vivo. Thus, in order to maintain effective concentration, protein therapeutics need to be 
administered by infusion or frequent injection [3]. Due to the limited route of 
administration, novel and effective alternatives to deliver protein therapeutics is an 
important issue for protein therapeutics’ application in biotechnology and pharmaceutical 
industry.  
1.2 Overview of Controlled Release Drug Delivery 
For many years researchers have sought to develop advanced drug delivery systems 
which can target drugs to specific body sites and precisely control drug release rates for 
prolonged time [4]. In order to be effective and limit side effects, in vivo drug 
concentration should be maintained within the so-called therapeutic window, which 
consists of a lower bound, the minimum effective concentration (MEC), and an upper 
bound, the minimum toxic concentration (MTC), as illustrated in Figure 1.1. For 
conventional drug delivery methods, such as oral dosing and injection, peaks and valleys 
typically appear in the concentration profiles, which lead to side effects and the need for 
frequent administration. One of the reasons to consider controlled drug release is to 
maintain drug concentration within the therapeutic window for a prolonged time with 
reduced dosage frequency, thus increasing patient compliance.  
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Figure 1. 1: Illustration of the drug concentration curve after taken into human body and therapeutic 
window for drug delivery (MTC: minimum toxic concentration; MEC: minimum effective concentration). 
 
 With an explosion in research aimed at creating new drug delivery systems, many 
new controlled release systems have been developed and commercialized such as 
polymer-based systems, liposome-based delivery systems and microchip intelligent 
delivery systems [4]. These systems can not only maintain drug concentration within the 
therapeutic window for an extended time after initial dose but can also protect some 
fragile therapeutics [5].  
1.3 Biodegradable Polymer Microparticles for Protein Delivery 
Among all the controlled delivery devices, biodegradable polymers have been widely 
utilized as a means to deliver therapeutics in a controlled and minimally invasive manner 
[6-8]. Compared to non-biodegradable polymers which may pose problems of toxicity 
and are difficult to remove, biodegradable polymer devices have attracted much attention 
since early 1970s. Interests in biodegradable polymer development are mainly for two 
reasons: there is no need of surgical removal of polymer devices, and non-biodegradable 
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diffusion-controlled delivery systems are limited by polymer permeability and drug 
characteristics [8]. Specifically, biodegradable depots such as rods, wafers, microspheres, 
double-wall microspheres and microcapsules have been shown to provide controlled 
release for small-molecule drugs as well as macromolecules such as proteins and DNA 
[9-11]. 
 Microparticles exhibiting size ranging from a few to several hundred microns 
have received much attention in academia and industry. For example, monodisperse 
microspheres approximately 1-5 µm in diameter would be ideal for passive targeting of 
professional antigen-presenting cells [12, 13]. Microspheres 10-20 µm in diameter could 
be used to target the tortuous capillary bed of tumor tissues by chemo-embolization [14]. 
Microparticles 1-5 µm in diameter and highly porous particles 5-20 µm in diameter are 
effective pulmonary drug delivery vehicles [4]. Microspheres 20-100 µm are less 
myotoxic than microspheres less than 5 µm [15]. Also, a major reason for microparticles 
10-100 µm in diameter receiving much attention is that they are small enough for syringe 
injection and also large enough to not be carried away from the injection site by 
phagocytic cells. Due to the simplicity and versatility of these microparticle devices, 
many commercialized products have been produced. For example, Trelstar® injectable 
PLG microspheres and Lupron® depot for prostate cancer, Sandostatin LAR® PLG 
depot for acromegaly, Risperdal® Consta® PLG depot for the treatment of schizophrenia 
as well as for the longer-term treatment of Bipolar I disorder and Vivitrol® PLG depot 
for alcohol dependence are all commercialized implantable or injectable biodegradable 
devices [16]. Furthermore, biodegradable microparticles offer several advantages such as 
high local drug concentrations at the site of administration, good protection of fragile 
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therapeutics and minimized side effects. For protein therapeutics specifically, the simple 
fabrication process and programmable degradation rates of polymers make biodegradable 
microparticles a promising delivery system. 
1.3.1 Choice of Biodegradable Polymers 
Three classes of biodegradable polymers have been extensively investigated for drug 
delivery: polyesters, polyanhydrides and polyphosphoesters [17, 18]. Among them, the 
most frequently studied polymers are poly(lactide-co-glycolide) (PLG), and poly(lactic 
acid) (PLA). These two polymers both belong to the class of polyesters and their 
structures are shown in Figure 1.2. In this project, we focus on PLG and PLA, because 
their degradation kinetics, drug encapsulation capability and biocompatibility are well 
understood and a number of delivery systems based on these materials have been FDA 
approved. PLG and PLA degrade by hydrolysis of their ester linkages in the presence of 
water. Their chain scission by hydrolysis generates products with hydroxyl and acid end 
groups. These shorter segments may be further hydrolyzed to lactic and/or glycolic acid 
monomers.  
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Figure 1. 2: Structures of PLG (left) and PLA (right)  
 
 The degradation rate of PLG depends on the monomer ratio: the lower the content 
of glycolide units, the slower the degradation because increased lactide content leads to 
increased hydrophobicity of lactide over glycolide [19]. Thus PLA usually degrades 
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much slower than PLG. In addition, ester-end polymer degrades slower than carboxylic 
acid-end polymer because the acidic end group catalyzes the polymer degradation [19, 
20]. 
1.3.2 Fabrication Methods 
Fabrication methods of protein loaded biodegradable microparticles include solvent 
extraction/evaporation [21], polymer extrusion [22], spray drying [23], coacervation or 
precipitation [24] and microfluidic flow-focusing [25]. Although there are differences of 
these methods regarding the achievable size range and drug encapsulated, they have 
several features in common. Initially, biodegradable polymer should be dissolved in a 
suitable solvent such as dichloromethane or ethyl acetate. Then, the protein is co-
dissolved with that polymer, suspended as solid particulate or dissolved in another 
solvent (usually water) and emulsified with polymer solution. The protein-polymer 
suspension or emulsion is broken into droplets which are allowed to harden according to 
different fabrication methods. 
 Solvent extraction/evaporation is a common method used for producing protein-
loaded microspheres. In this method, polymer solution is emulsified in a non-solvent 
phase using homogenization or agitation. After emulsification, the polymer-protein 
droplets are stirred in the non-solvent bath so that the solvent can be extracted and 
allowed to evaporate. This method is simple, but the size control is poor resulting in 
broad size distribution. In Chapter 2, we will discuss the method of Precision Particle 
Fabrication, which is a modification of solvent extraction/evaporation that provides 
highly monodisperse microparticles.  
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 Extrusion methods fabricate microspheres by forcing microsphere constituents 
through a preformed porous membrane or an orifice. This method can achieve relatively 
narrow size distribution of microspheres [26, 27]. However, the high velocity of the 
stream inside the orifice and the shear force imparted may damage the encapsulated 
proteins. Besides, it is relatively hard to change the microsphere size.  
 For spray drying, an atomizer is engaged to produce droplets of the polymer-drug 
mixture, and a carrier stream of hot air is used for extracting the solvent. The resulting 
size distribution is relatively narrow since no other chemicals are involved during 
fabrication. However, the relatively high temperature and shear force of the carrier air 
stream may damage the proteins inside the particles. Besides, the spherical shape of 
microparticles is usually jeopardized due to the lack of control of carrier stream and 
solvent evaporation rate [28].  
 Coacervation methods rely on careful selection of polymer solvents as well as 
non-solvent. The solvent and non-solvent together promote phase separation of polymer 
into droplets around the protein encapsulated [29, 30]. The success of this process relies 
on and necessitates an understanding of the complex thermodynamics of phase separation 
and the resulting size distribution is typically broad. 
 Microfluidic flow-focusing method is a relatively new way to produce 
monodisperse microparticles with low cost. Flow-focusing devices with drug-loaded 
polymer flow and carrier stream within a microfluidic chip can make monodisperse 
polymer particles, both spherical and non-spherical [25]. Although it is easy to control 
the size distribution by changing relative flow rates within a microchip, it is relatively 
hard to scale up the production. 
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1.3.3 Protein Release Mechanism 
Protein may be released from PLG/PLA microparticles by three mechanisms: diffusion, 
chemical reaction and solvent activation [5]. Diffusion is the most common release 
mechanism for small-molecule drugs encapsulated in polymer depots. Small molecules 
may migrate from their initial position within the polymer depot to the surface area and 
finally to the outside media. Release by diffusion is generally dependent on the size of 
polymer depots. For protein therapeutics, however, the dimension of proteins makes 
diffusion much slower because proteins are too large and hydrophilic to diffuse through 
most polymeric materials. Usually, protein solution is emulsified within hydrophobic 
polymer materials, and during degradation and erosion of polymeric matrices, water-
filled pores form through which proteins could diffuse. The diffusion rate or effective 
diffusivity of protein is controlled by the rate of formation of water-filled pores. For 
proteins in powdered form, researchers discovered that matrices of solid hydrophobic 
polymers enabled protein molecules of nearly any size to be released for over 100 days 
[31].  
 Chemical reaction is accomplished by polymer degradation and erosion. 
Degradation is the act of individual polymer chain solvolysis and mainly hydrolysis to 
give lower molecular weight molecules. Erosion refers to mass loss from the overall 
polymer matrix. There are two types of erosion mechanism for commonly used 
biodegradable polymers in controlled release area: surface erosion and bulk erosion. At 
specific dimensions, for surface erosion, the solvent penetration rate is slower than 
polymer degradation rate. Thus polymer degrades and loses material primarily from the 
exposed surface area. For bulk erosion, the solvent penetration rate is faster than polymer 
9 
 
degradation rate and polymer degrades throughout the entire matrix. PLG and PLA 
undergo bulk erosion in controlled release devices of typical microscopic dimensions, 
which means protein may move through a complex porous path during bulk erosion. Also 
the erosion of polymers can affect the porous structure and accelerate protein release. 
 Solvent activation involves either swelling of polymer or osmotic effects. Devices 
that control the flow of protein solutions utilize osmotic potential gradients across 
polymer barriers to generate pressurized chambers containing aqueous solutions of 
protein. This pressure is relieved by the flow of protein solution out of the delivery device 
[32].  
 For protein-loaded PLG/PLA depots, the release mechanism can be combinations 
of the three mechanisms. Upon immersing depots such as microparticles within an 
aqueous buffer, water penetrates toward the matrix center. Since PLG/PLA microspheres 
are bulk-eroding devices, water penetration rate is faster than the rate of polymer 
hydrolysis, and degradation of PLG/PLA copolymers occurs throughout the matrix 
volume.  During this degradation and swelling phase, water-filled pores form and grow in 
size, and the effective diffusivity of protein increases. Protein will diffuse through these 
pores out of the matrices, and the release rate is controlled by effective diffusivity and 
rates of pore formation.  
 Protein release profiles from biodegradable polymer microparticles typically 
comprise three phases: the initial burst, the lag phase and the steady release phase [33, 
34]. The initial burst, a relatively fast release of protein within a short period, may be due 
to the protein attached to the surface of microparticles, protein near the periphery and 
protein encapsulated inside small microparticles. The initial burst is followed by a lag 
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phase of slow protein release due to low diffusivity of large size protein through 
relatively dense microparticles and a final phase of steady, relatively rapid drug release 
governed by higher effective diffusivity through water-filled pores developed within 
microparticles. A typical protein release profile is shown in Figure 1.3. 
 
Figure 1. 3: Hypothetical protein release profile from biodegradable microparticles [10] 
 
 PLG/PLA microparticle diameter is intricately related to the degradation rate and 
protein release properties. For large particles, water penetration takes longer time and the 
formation of water-filled pores is slow. The relatively long diffusion distance and slow 
pore formation rate can lead to slower protein release rate. However, larger PLG/PLA 
microparticles accumulate an increased amount of acidic degradation byproduct, leading 
to an acidic microenvironment inside [35]. This reduced pH can further catalyze the 
degradation and erosion of PLG/PLA. This process is called autocatalysis and can lead to 
the counter-intuitive result of fast protein release from large microparticles [19]. 
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1.4 Double-wall Microspheres and Liquid-core Microcapsules 
Double-wall microspheres (DWMS), comprising two distinct polymer core and shell 
phases, and liquid-core microcapsules (MC), comprising aqueous/oil core and polymer 
shell phase, are versatile and useful release systems and are extensively studied in 
academia. The most important feature of core-shell structure in DWMS and MC can 
provide unique opportunities to control drug release rates [36-42]. DWMS and MC offer 
several advantages compared to conventional monolithic microspheres or single-wall 
microspheres (SWMS): firstly, drug encapsulated in the core of DWMS or MC may 
overcome the problem of high initial burst release commonly encountered in SWMS [43-
45]; secondly, higher loading with improved drug stability may be achieved by using 
materials in the core phase that offer increased drug solubility [46]; thirdly, drug release 
rates may be controlled by controlling the shell material or thickness [47, 48]; finally, 
drugs can be released either in a sequential or simultaneous manner by selectively 
loading them into the core or shell phase, therefore potentially enhancing drug efficacy 
[49-53].  
1.4.1 Conventional Fabrication Methods 
For producing DWMS, the traditional solvent extraction/evaporation method can be used. 
Two polymers are dissolved in a volatile organic solvent such as dichloromethane or 
ethyl acetate. The solution is then added into an aqueous solution containing surfactant 
and stirred. As the polymers become concentrated, they begin to phase separate and form 
the core-shell structure DWMS [37]. This oil-in-water (O/W) method can produce 
DWMS with core and shell polymers at their thermodynamically stable configurations 
according to the spreading coefficient theory [54, 55]. The oil-in-oil-in-water (O/O/W) 
12 
 
method was used for producing DWMS by different researchers. Lee et al. fabricated 
etanidazole-loaded DWMS using dichloromethane as organic solvent. First, separate 
solutions of PLA and PLG in dichloromethane were prepared. The etanidazole was co-
dissolved in dichloromethane with PLG. The two polymeric solutions were then added 
together and sonicated or homogenized to create an oil-in-oil (O/O) emulsion. Addition 
of the emulsion dropwise into non-solvent solution created an O/O/W emulsion. The 
emulsion was stirred to allow for the extraction and evaporation of dichloromethane as 
well as the hardening of the DWMS [56]. Kokai et al. used a similar O/O/W emulsion 
method to produce solid lysozyme-loaded DWMS [57]. Sanchez et al. used the O/O/W 
emulsion method to produce DWMS with solid protein powder-loaded oil core MC. Fine 
particles of protein powder were dispersed in mineral oil using a high-speed homogenizer. 
The suspension was dispersed in PLG acetonitrile/ethyl acetate mixture solution with 
agitation to produce the O/O emulsion. The resulting organic phase was poured through a 
narrow orifice into the aqueous non-solvent solution with stirring to produce the O/O/W 
oil core MC [38].  
 Besides emulsion methods, layer-by-layer deposition on sacrificial template 
particles was also used for producing nano- or micro-scale MC [58]. This method 
involves the deposition of layer-by-layer film components onto the outer surface of 
colloidal particles that are subsequently removed via chemical or thermal means [59, 60]. 
 For these methods, the control of DWMS and MC dimensions such as outer 
diameter and shell thickness are typically poor. The emulsion method can produce 
DWMS and MC with relatively broad size distribution and the polymer orientation for 
core and shell may change during fabrication. For layer-by-layer coating, the diameter 
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and shell thickness of MC can be very uniform but these dimensions are controlled by the 
templates. Besides, this method possesses limitations when generating thick layers or 
encapsulating a liquid core [61]. 
1.4.2 Protein Encapsulation and Release 
DWMS and MC have been also studied for protein therapeutics delivery. Sanchez et al. 
reported using oil-core PLG MC for tetanus toxoid delivery. Tetanus toxoid powder was 
suspended in the mineral oil core phase and surrounded by PLG shell phase. After an 
initial burst, the systems released tetanus toxoid in a pulsatile manner. Kim et al. 
produced insulin-loaded PLG MC using a monoaxial ultrasonic atomizer. When the 
protein solution and the PLG solution were mixed, a water-in-oil (W/O) emulsion was 
formed within a few seconds. The atomization process resulted in the formation of 
microdroplets of aqueous solution surrounded by PLG solution. The in vitro release 
profile of insulin consists of two parts: a fast initial burst on the first day, followed by a 
slow, smooth release for up to 30 days [62]. Kokai et al. using the oil-in-oil-in-water 
(O/O/W) emulsion method produced DWMS with PLA and PLG. Initial studies with 
DWMS encapsulating a fluorescently tagged protein, FITC-BSA, indicated that protein 
localization was restricted to the PLG core. Protein in vitro release was performed using 
DWMS with the model protein lysozyme encapsulated alone or with the surfactant 
docusate sodium salt (AOT). Degradation studies showed that DWMS encapsulating 
lysozyme alone resulted in a core composition of PLG and a shell composition of PLA. 
In contrast, the polymer orientation of core and shell were reversed due to AOT addition 
in the PLG solution [57]. 
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1.5 Project Overview 
In this project, we use uniform PLA(PLG) DWMS (PLA as shell material and PLG as 
core material), PLG(Liquid) MC (PLG as shell material and emulsion of canola oil and 
protein solution as core material) to study protein encapsulation and release. Figure 1.4 
shows the schematic of DWMS and MC. We apply Precision Particle Fabrication (PPF) 
technology to produce SWMS, DWMS and MC with uniform outer diameter and shell 
thickness. By eliminating the interferences of particle size/structure, we can study the 
release profiles of a model protein, bovine serum albumin (BSA), encapsulated in the 
core of DWMS or MC.  
 
 
Figure 1. 4: Schematic of PLA(PLG) DWMS and PLG(Liquid) MC 
 
 For DWMS structure, we use PLG as the core material and BSA encapsulated 
within PLG using double-emulsion method. The shell material is slow degrading PLA. 
We will study the relation between PLA(PLG) DWMS composition, structural properties 
and BSA release profiles. Similar experiments are carried out for PLG(Liquid) MC. 
Using microscopic methods, we are able to examine the particle surface and interior 
morphology initially and during degradation in release buffer as well as protein 
distribution.  
 In Chapter 2, we describe the development of PPF nozzle systems to successfully 
fabricate monodisperse DWMS/MC as well as SWMS. Chapter 3 focuses on the study of 
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BSA encapsulation and release from DWMS with different PLG and PLA molecular 
weight. In Chapter 4, the structural properties (overall diameter and shell thickness) of 
DWMS are explored for BSA encapsulation and long-term release. In Chapter 5, we 
investigate using liquid-core MC to encapsulate and deliver BSA. Liquid-core MC with 
different PLG molecular weight and shell thickness are applied to understand the ability 
of MC system for therapeutic protein delivery. Finally, in Chapter 6, we propose several 
future works related to this project.  
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Chapter 2. Nozzle Systems for Precision Particle Fabrication 
2.1 Precision Particle Fabrication 
2.1.1 Method Description 
Precision Particle Fabrication (PPF) is a technology developed to produce monodisperse 
particles of a variety of materials [1-4] and applied by our group for fabrication of 
controlled-release devices comprising biodegradable polymers [5-16]. Figure 2.1 shows 
the experimental set up for PPF. 
 
 
Figure 2. 1: Schematic of PPF apparatus for fabrication of DWMS/MC (A) and SWMS (B) 
 
 The PPF apparatus consists of a pump system, frequency generator, nozzle system, 
collecting system and visualization system. The pump system has one gear pump (IP65, 
ISMATEC) which is used to carry the non-solvent carrier stream, and two syringe pumps 
(Pump 11, Harvard Apparatus) are used to carry the polymer/drug solution(s). For 
double-wall microsphere (DWMS) and microcapsule (MC) fabrication, both syringe 
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pumps are employed: one for the core phase and the other for the shell phase. The non-
solvent carrier stream (0.5-1% w/v poly(vinyl alcohol) (PVA) in water) is carried by the 
gear pump. For single-wall microsphere (SWMS) or monolithic microsphere fabrication, 
only one syringe pump is used to deliver the polymer phase. The frequency generator 
(Agilent 33200A) and piezoelectric transducer (cv 33, Sonic and Materials Inc.) generate 
an acoustic wave on the nozzle system to break the laminar polymer-containing stream 
into a train of uniform droplets. We can control the amplitude and frequency of the 
acoustic wave together with the polymer and carrier stream flow rates to produce 
microparticles with desired diameters and structures [5, 15, 16]. 
 The nozzle system is the key part of PPF. A triple nozzle system for producing 
DWMS or MC and a double nozzle system for producing SWMS or monolithic 
microsphere were manually produced. For the triple nozzle system, we use a hypodermic 
needle (PrecisionGlide, Becton Dickinson Co.) as the inner metal nozzle, which is 
surrounded coaxially by the inner glass nozzle made of a glass capillary. The outer glass 
nozzle is made of Pyrex glass. For DMWS and MC fabrication, the core phase 
polymer/aqueous/oil stream passes through the inner metal nozzle, and the shell phase 
polymer stream passes through the inner glass nozzle. The outer glass nozzle is for non-
solvent carrier stream, which is used to facilitate the forming of round shape particles and 
providing “drag force” in order to produce particles smaller than the nozzle opening [7, 
8]. For the double nozzle system, one hypodermic needle is used as inner metal nozzle 
which is surrounded by the inner glass nozzle. There is no outer glass nozzle in this 
setting. The drug-polymer stream passes through the inner metal nozzle, and carrier 
stream passes through inner glass nozzle. 
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 The collecting system, which is used to collect and harden the nascent particles, 
consists of a non-solvent bath in a 500 mL glass beaker with a stirring bar. Enough non-
solvent to dissolve all organic solvents within particles in the collecting beaker should be 
provided [17, 18]. 
 The visualization system consists of a strobe light (Nova Strobe BA, Monarch 
Instrument) and a video camera (EO Edmund, industrial optics) which is connected to a 
monitor. By adjusting the frequency of the strobe light to match the frequency of the 
acoustic wave, we can get a steady picture of the droplets stream and so monitor the 
formation of microparticles.  
2.1.2 Theory 
The main apparatus of PPF, which provides fabrication of monodisperse microparticles, 
is based on passing a fluid containing the sphere materials and any drug to be 
encapsulated through a small (10-100 µm) orifice in the nozzle system to form a smooth, 
cylindrical stream. To break the stream into droplets, the nozzle is vibrated by a 
piezoelectric transducer driven by an acoustic wave generator at certain frequency. The 
acoustic energy along the stream generates periodic instabilities that break the stream into 
a train of uniform droplets. With only a single nozzle, the minimum particle size 
achievable is slightly larger than the nozzle opening [5, 6, 11]. By employing an annular 
flow of a non-solvent phase, known as the carrier stream, through a second concentric 
nozzle, microparticle size and shape can be further controlled. The carrier stream is 
pumped by the gear pump at a linear velocity greater than that of the inner polymer 
stream. The frictional contact between the two streams can generate an additional 
downward force which “pulls” the polymer stream away from the nozzle system. 
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Accelerated by this force, the polymer stream is thinned to a degree depending on the 
difference in linear velocities of the two streams. 
 To achieve the desired microparticle diameter, theory of the droplet formation 
needs to be specified. Lord Rayleigh first derived the jet instability equations for a 
cylindrical jet subject to disturbance [19]. He found that the most unstable wavelength 
(λmax) of a disturbance imposed on a jet surface is: 
                                (2.1) 
where rj is the radius of the undisturbed jet flow. The theoretical range of wavelengths 
that still results in the production of uniform droplets was derived by Lord Raleigh to be: 
                                   (2.2) 
Above a certain wavelength, the instability growth is so small that noise near the 
wavelength of the applied acoustic wave causes random breakup of the jet. So the actual 
range of acoustic wavelengths which can break up a liquid jet into uniform droplets was 
experimentally determined to be [20]: 
                                   (2.3) 
The frequency generator of PPF allows for control of the acoustic wave frequency and 
amplitude. The wavelength produced by a set frequency (f) is given by: 
                                      (2.4) 
where vj is the linear velocity of the liquid jet. Knowing that the volume of the spherical 
droplet should be equal to the volume of a cylindrical element of the jet (5), the length of 
which is defined by the acoustic wavelength, we can find that the droplet radius, rd, is 
given by (6). 
 
 
     
      
        
  
  
 
        (2.5) 
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             (2.6) 
At the optimum wavelength (substituting equation (2.1) into (2.6)), rd,max=1.891rj. Thus, 
by imposing acoustic wave on the nozzle, we can control the breakup of the stream into 
droplets and predict the nozzle opening size (~rj), solution flow rate (vj) and acoustic 
wave frequency (f) needed to generate the desired particle size [7]. 
 For this project, a triple nozzle system and a double nozzle system with a fixed 
nozzle opening are used to produce different samples. By changing the flow rate of the 
polymer stream, we can produce droplet sizes close to what we desired. Using equation 
(2.6), by changing acoustic wave frequency, we can make the minor adjustment of the 
particle size to within 1 micron. 
2.2 PPF Nozzle System Optimization 
As mentioned before, the nozzle system is the key part of the whole PPF apparatus. A 
“well-behaved”, reliable and sturdy nozzle system plays the most important part of 
successful particle fabrication. We tried several combinations of the outer glass nozzle, 
inner glass nozzle and inner metal nozzle and found that the inner curvature and the 
dimension of the nozzles are important for successful particle fabrication. 
2.2.1 Nozzle System Configuration 
The nozzle settings of triple nozzle system and double nozzle system (Figure 2.2) are 
assembled using commercialized cheminert fittings® (VICI Valco Instruments Co. Inc.). 
Triple nozzle system and double nozzle system are all composed of a metal nozzle and 
glass nozzle(s). Inner metal nozzles are for core polymer stream in both settings. For 
triple nozzle system, there is an inner glass nozzle for shell phase and an extra outer glass 
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nozzle for carrier stream. For double nozzle system, only inner glass nozzles are 
employed for carrier stream. All metal nozzles are flat end commercial hypodermic 
needles and all glass nozzles are glass capillaries in which one end is melted closed and 
sanded open manually. These coaxial nozzle systems are tested using PLG polymer 
solution. Good nozzle systems can reproducibly produce steady particle streams without 
breaking and clogging frequently.   
 
 
Figure 2. 2: Triple nozzle system (left) and double nozzle system (right) 
 
2.2.2 Curvature of Nozzles 
The outer Pyrex glass nozzle and inner glass nozzle are both manually produced via a 
similar process. For Pyrex glass outer nozzle, glass tubing is cut into approximately 1-
inch long piece. We slowly rotate and melt one end of the Pyrex tube in a propane flame 
until the end is sealed, then sand the closed end on a sandpaper until a small opening (1/5 
to 1/4 of the inner diameter) is exposed. The dimension of the opening should not be 
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either too small (blocked frequently) or too big (generate unsteady jet). For inner glass 
nozzle, we use commercial Borosilicate glass capillary (World Precision Instrument, Inc.). 
Six types of capillary with different outer diameter (OD) and wall thickness (WT) are 
available: 1.0 mm R (OD=1.0 mm, WT=0.21 mm), 1.0 mm TW (OD=1.0 mm, WT=0.13 
mm), 1.2 mm R (OD=1.2 mm, WT=0.26 mm), 1.2 mm TW (OD=1.2 mm, WT=0.15 
mm), 1.5 mm R (OD=1.5 mm, WT=0.33 mm), and 1.5 mm TW (OD=1.5 mm, WT=0.19 
mm). Figure 2.3 shows the outer glass nozzle and six types of inner glass nozzles. 
 
 
 
Figure 2. 3: Outer and inner glass nozzles after melting the ends and sanding to form the nozzle openings.  
 
 Using PLG polymer solutions (PLG 3-10% w/v in DCM) and 0.5-1 % (w/v) PVA 
as carrier stream, we tested the behavior of glass nozzles to form steady, uniform droplets 
using PPF. We found that the inner curvatures of outer and inner glass nozzles played an 
important role in forming steady trains of droplets. The “well-behaved” nozzles all had 
“blunt” inner curvatures while the “poorly-behaved” nozzles had “sharp” inner curvatures 
(Figure 2.4). 
 The reason for this phenomenon might be that the “blunt” inner curvature would 
lead the laminar flow of polymer solution in a smooth way through the nozzle opening 
while the “sharp” inner curvature would cause turbulence when the flow hits the 
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boundary between curved nozzle wall and flat bottom. Also, for inner glass nozzle, “blunt” 
inner curvature was crucial and if the outside of the nozzle head was tapered to give more 
room for carrier stream within outer and inner glass nozzles (Figure 2.3 1.5 mm R), the 
jets coming through the nozzles would be more steady and smooth. 
 
 
 
Figure 2. 4: “Poorly-behaved” (left) and “well-behaved” (right) inner glass nozzles  
 
2.2.3 Dimensions of Nozzles 
The dimensions of inner glass nozzle and inner metal nozzles were also examined for 
their effects on production of steady droplet streams. We had only one type of outer glass 
nozzle which was Pyrex glass tube (OD=2.5 mm, TW=0.5 mm), six types of inner glass 
capillary (1.0 mm R, 1.0 mm TW, 1.2 mm R, 1.2 mm TW, 1.5 mm R, 1.5 mm TW) and 
three types of hypodermic needle as inner metal nozzles (gauge 23, gauge 25 and gauge 
27). By screening different combinations using PLG solutions (PLG 3-10% w/v in DCM) 
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and 0.5-1 % (w/v) PVA as carrier stream, we found the proper configuration of triple 
nozzle system and double nozzle system. Table 2.1 shows the results of the screening. 
 We found for triple nozzle system, the optimum nozzle setting was: Pyrex glass 
tube (OD=2.5 mm, WT=0.5 mm), inner nozzle (1.5 mm R), inner metal nozzle (gauge 23, 
25). For double nozzle system, the optimum nozzle setting was simply the optimum triple 
nozzle system configuration without outer Pyrex glass nozzle. 
 
Table 2. 1: Nozzle configuration screening for PPF 
Outer Glass Nozzle Inner Glass Nozzle Inner Metal Nozzle Results 
OD=2.5 mm WT=0.5 mm 1.0 mm TW gauge 27 Glass nozzle broke frequently 
OD=2.5 mm WT=0.5 mm 1.0 mm R gauge 27 Could not form droplets 
OD=2.5 mm WT=0.5 mm 1.2 mm TW gauge 25, 27 Glass nozzle broke frequently 
OD=2.5 mm WT=0.5 mm 1.2 mm R gauge 25, 27 Hard to form droplets 
OD=2.5 mm WT=0.5 mm 1.5 mm TW gauge 23, 25, 27 Glass nozzle broke frequently 
OD=2.5 mm WT=0.5 mm 1.5 mm R gauge 23, 25 No major problems 
N/A 1.5 mm R gauge 23, 25 No major problems 
 
2.3 Conclusions 
Precision Particle Fabrication technology can produce monodisperse microparticles at 
desired diameter by changing nozzle opening, polymer flow rate and frequency of 
acoustic wave. 
 The nozzle system is the most important part of the whole PPF and is responsible 
for successful uniform particle fabrication. Through several trials, we found that the 
performance of “blunt” inner curvature nozzles in producing steady, uniform particle 
streams was much better than that of nozzles with “sharp” inner curvatures. Also, 
different combinations of the inner glass nozzles and inner metal nozzles have significant 
impact on nozzle behavior. 
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 After screening, we found the optimum configuration of triple nozzle system (for 
producing DWMS and MC) and double nozzle system (for producing SWMS or 
monolithic microsphere) shown in Table 2.2. Micrographs of optimized triple and double 
nozzle system are shown in Figure 2.5.  
 
Table 2. 2: Triple/double nozzle system configuration for PPF 
Triple Nozzle System Double Nozzle System 
Outer Glass Nozzle N/A Outer Glass Nozzle OD=2.5 mm; WT=0.5 mm 
Inner Glass Nozzle  1.5 mm R Inner Glass Nozzle 1.5 mm R 
Inner Metal Nozzle gauge 25 Inner Metal Nozzle gauge 23 
 
 
 
Figure 2. 5: Optimized triple (left) and double (right) nozzle systems 
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Chapter 3. Uniform DWMS with Different Polymer Composition for Protein 
Delivery 
Preface 
Portions of the following chapter are adapted from a previous publication: “Protein 
encapsulation in and release from monodisperse double-wall microspheres”, Y. Xia, Q. 
Xu, C.-H. Wang, D.W. Pack. J. Pharm. Sci., 102 (2013) 1601-1609 (© 2013, Wiley) 
3.1 Introduction 
Biodegradable polymer devices such as microspheres, rods and disks have been utilized 
as a means to deliver drugs in a controlled, predictable and minimally invasive manner 
[1-3]. In particular, spherical microparticles with sizes ranging from a few to several 
hundred microns have been shown to provide controlled release of small-molecule drugs 
as well as macromolecules [4-7], and several products have been commercialized. 
Biodegradable polymer particles offer several advantages such as minimally invasive 
administration, potential for high localized drug concentrations near the site of 
administration, relatively simple fabrication, and protection of fragile therapeutics. A 
limitation of these systems, however, is the difficulty of controlling drug release rates and, 
in particular, obtaining constant rate of release for prolonged times. Several approaches 
have been employed, with mixed success, to provide flexibility and control of drug 
release rates including (i) choice of polymer chemistry [8], (ii) conjugating drugs to the 
polymer [9], (iii) varying physical characteristics of particles [6, 10-13], (iv) controlling 
particle size and size distribution [14-22], and (v) modifying particle structure [23-27].  
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 Double-wall microspheres (DWMS), comprising a drug-loaded polymer core 
surrounded by a drug-free shell of the same or a different polymer, are promising devices 
for controlled release applications. DWMS are often fabricated by variations of the 
conventional emulsion/solvent extraction method, and formation of the core-shell 
structure is driven by phase separation of the two polymer components [28, 29]. Such 
methods typically produce DWMS with a broad distribution of size and shell thickness, 
and are limited to immiscible core and shell polymers at their thermodynamically stable 
configurations [30, 31]. 
 Using the precision particle fabrication technique (PPF) [32-35], however, we 
produced monodisperse DWMS with poly(lactide-co-glycolide) (PLG) cores and 
poly(lactic acid) (PLA) shells of uniform thickness. The model protein bovine serum 
albumin (BSA) was encapsulated in the PLG core phase, and the PLA shell did not 
contain drug. Also BSA-loaded PLG monolithic single-wall microspheres (SWMS) were 
produced to mimic the PLG core in DWMS. We hypothesized that the drug free PLA 
layer of DWMS would provide better protein encapsulation efficiency as well as 
postpone protein release compared to SWMS. 
 In this study, we examined the influence of polymer solvents and molecular 
weights on the DWMS formation process, protein encapsulation and in vitro protein 
release rates. In addition, investigation of DWMS thermal properties, morphology, 
intraparticle protein distribution, and particle erosion provides insights into the 
mechanism of BSA release. 
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3.2 Materials and Methods 
3.2.1 Materials 
Poly(D,L-lactide-co-glycolide) (PLG, Mw 4.2 kDa, 15 kDa and 38 kDa; lactide: glycolide 
50:50) and two poly(lactic acid) (PLA) isomers: poly(D,L-lactic acid) (PDLLA, Mw 38 
kDa, 43 kDa, 106 kDa) and poly(L-lactic acid) (PLLA, 192 kDa) were purchased from 
LACTEL Absorbable Polymers. Chromatography grade ethyl acetate (EtAc) and 
dichloromethane (DCM) were obtained from Sigma-Aldrich. Bovine serum albumin 
(BSA, Mw 66,700 Da) and dimethyl sulfoxide (DMSO) were purchased from Fisher 
Scientific. Fluorescent dye 5-(and-6)-carboxytetramethylrhodamine succinimidyl ester 
(TAMRA) was obtained from Molecular Probes. Poly(vinyl alcohol) (PVA, Mw 25,000 
Da, 88% hydrolyzed) was purchased from Polysciences. Tween 80 was purchased from 
Acros Organics.  
3.2.2 Double-wall and Single-wall Microspheres Fabrication 
BSA (100 mg/mL in deionized water) was emulsified with PLG in DCM or EtAc (10% 
w/v) at a volumetric ratio of 1:10 aqueous:organic by sonication (CE Converter 102 C, 
Branson) at 60% amplitude for 1 min to form the core phase. The shell phase was 3% w/v 
PLA dissolved in DCM or EtAc. PVA water solution (0.5% w/v) was used as non-solvent 
carrier stream.  
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Table 3. 1: PPF parameters for single-wall microspheres/double-wall microspheres 
 Single-wall microspheres Double-wall microspheres 
Nozzle Configuration Double Nozzle System Triple Nozzle System 
Shell Flow Rate (mL/hr.) 0 36 
Core Flow Rate (mL/hr.) 4 4 
Wave Amplitute (V) +5.00 (Maximum) +5.00 (Maximum) 
Wave Frequency (KHz) 7.5 5 
Wave Type Sine Sine 
PVA Flow Rate (mL/hr.) 150-500 500-1100 
 
For DWMS fabrication, the concentric triple nozzle system was used. The core 
phase PLG/BSA emulsion passed through an inner metal nozzle, and the shell phase PLA 
solution passed through a concentric glass nozzle. An outermost glass nozzle was used 
for PVA non-solvent carrier stream, which allowed production of particles smaller than 
the nozzle opening [17, 18]. For SWMS, the double nozzle system was employed, in 
which the core phase PLG/BSA emulsion passed through an inner metal nozzle, and a 
concentric glass nozzle was used for the PVA carrier stream. A frequency generator 
(Agilent 33220A) and piezoelectric transducer (CV33, Sonic & Materials Inc.) generated 
an acoustic wave on the nozzle system to break the exiting polymer streams into uniform 
droplets (Figure 2.1, Figure 2.2). PPF fabrication parameters of DWMS and SWMS are 
shown in Table 3.1. Nascent DWMS and SWMS were collected in a 500 mL beaker 
containing 200-500 mL of 0.5% w/v PVA solution and were stirred for 3 h for organic 
solvent extraction and evaporation. The particles were filtered (Filter Paper #4, 
Whatman), washed three times by deionized water, and lyophilized for 48 h. Samples 
were stored until use in a -20 
o
C freezer with desiccant. 
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3.2.3 Particle Size Distribution 
The size distributions of nascent particles (wet particles before lyophilizing) were 
determined using a Coulter Multisizer III (Beckman Coulter Inc.) with a 200 µm aperture 
in Isoton II. More than 10,000 particles were measured for each sample. 
3.2.4 Protein Loading 
Samples of approximately 5 mg were dissolved in 100 µL DMSO. The solution was 
pipetted into 1 mL of phosphate-buffered saline (PBS, pH 7.4±0.05) then incubated for 1 
h at 37 
o
C with shaking at 240 rpm. The mixture was centrifuged for 10 minutes at 
10,000 rpm, and BSA concentration in the supernatant was determined using BCA assay 
(Pierce). All absorbance measurements were taken on a SpectraMax 340 PC reader 
equipped with SoFTMax Pro software. The loading equaled the mass of BSA per mass of 
particles. The encapsulation efficiency equaled the actual BSA loading divided by 
theoretical BSA loading multiplied by 100. 
3.2.5 BSA In Vitro Release 
For each batch of DWMS or SWMS, a sample of approximately 30 mg was suspended in 
1.25 mL release buffer consisting of 0.05% (v/v) Tween 80 (to prevent particle 
agglomeration) and PBS, pH 7.4. These samples were incubated at 37 
o
C with shaking 
(240 rpm). At various time points, 1.0 mL supernatant was removed and replaced with 
fresh media in order to maintain constant pH sink condition. Blank DMWS or SWMS 
(same fabrication parameters, except no protein was added) were treated the same way 
and the supernatants at various time points were collected as controls. The release study 
was performed in triplicate, and BSA concentrations in the collected supernatants were 
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measured using BCA assay (Pierce) with absorbance corrected by absorbance of 
supernatants from blank microspheres. 
3.2.6 Confocal Fluorescence Microscopy 
Twenty milligrams of BSA were dissolved in 2 mL of sodium bicarbonate (Fisher) at pH 
8.3±0.05. A solution of 1 mg TAMRA in 100 µL DMSO (Fisher) was then pipetted into a 
foil-wrapped vial containing the BSA solution. The solution was stirred for 60 minutes at 
room temperature and then separated using PD-10 desalting column (GE Healthcare). 
The labeled protein was collected from the column, frozen, and lyophilized. The degree 
of labeling (DoL, the number of TAMRA molecules attached to each protein molecule) 
as determined from the relative absorbances of TAMRA (555 nm) and BSA (280 nm) 
was 3.40. Particles were loaded with 5% of TAMRA-labeled BSA and 95% unlabeled 
BSA. 
 Fluorescence and transmitted light images of the protein-loaded DWMS and 
SWMS were obtained with a Leica SP2 laser confocal microscope with a 63x oil-
immersion lens. Fluorescence was excited using a HeNe laser (543 nm) and emission 
collected with a 575-640 nm band-pass filter.  
3.2.7 Particle DSC Study 
Differential Scanning Calorimetry (DSC) was performed on each batch of microparticles 
as well as pure polymers to study their thermal properties such as glass transition 
temperatures (Tg) and melting temperature (Tm). Perkin Elmer Pyris Diamond DSC was 
used, and all samples were heated from -10 
o
C to 200 
o
C at 10 
o
C/min. 
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3.2.8 Scanning Electron Microscopy (SEM) 
DWMS and SWMS were prepared for imaging by placing a droplet of an aqueous 
particle suspension on a silicon stub. The samples were dried overnight and sputter 
coated with gold and platinum prior to imaging. In order to image the cross-sections, 
microspheres were frozen in liquid nitrogen and fractured using a razor blade on a glass 
slide, resuspended in a water droplet, and mounted on silicon stubs.  The JEOL 6060 LV 
scanning electron microscope was used at an acceleration voltage of 5-20 kV. 
3.2.9 Particle Degradation/Erosion Study 
For each batch of DWMS or SWMS, a sample of approximately 5 mg was suspended in 
1.25 mL release buffer consisting of 0.05% (v/v) Tween 80 and PBS. These samples 
were incubated at 37 
o
C with shaking (240 rpm). At various time points, all supernatant 
was removed and the samples were frozen and lyophilized for at least 48 h. The samples 
were prepared for SEM as described above. 
3.3 Results 
3.3.1 Production of BSA-loaded DWMS 
To prepare DWMS, the PLG core and PLA shell materials were dissolved in either EtAc 
or DCM. Using DCM as both core and shell solvent (denoted as DCM(DCM), Figure 
3.1A), the particle size distribution was 54.8±1.4 µm. Using EtAc as shell solvent and 
using DCM as core solvent (EtAc(DCM), Figure 3.1B), the particle size distribution was 
55.1±2.0 µm. In both cases some particles smaller than the desired diameter were formed, 
but the volume percent of the main peaks were ~70%. However, when EtAc was used as 
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core solvent with either DCM or EtAc as the shell solvent (DCM(EtAc), EtAc(EtAc)), 
the particle uniformity was poor (Figure 3.1 C, D).  
 We investigated the effects of PLG and PLA molecular weight on particle 
fabrication and BSA encapsulation. PLG SWMS were also fabricated to mimic the PLG 
core in the DWMS. The three sets of experiments were (i) using EtAc(DCM) solvent 
configuration at constant PLG core molecular weight (4.2 kDa), while increasing PLA 
shell molecular weight (43 kDa, 106 kDa); (ii) using EtAc(DCM) solvent configuration 
at constant PLA shell molecular weight (38 kDa), while increasing PLG core molecular 
weight (4.2 kDa, 15 kDa, 38 kDa); and (iii) using DCM(DCM) solvent configuration at 
constant PLG core molecular weight (4.2 kDa), while increasing PLA shell molecular 
weight (43 kDa, 106 kDa, 192 kDa).  
 For calculation of DWMS shell thickness, assuming no polymer mass loss during 
PPF fabrication process, volume additivity and concentric core-shell structure of DWMS, 
core diameter and shell thickness of DWMS can be calculated using following equations: 
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 ̇    and  ̇    are volumetric flow rates of PLA and PLG, respectively (cm
3
/hour);      
and      are the concentrations of PLA and PLG in organic solvents (g/cm
3
);            
and           are the densities of organic solvent in shell and core phase (g/cm
3
);        
and       are densities of shell and core phases (g/cm
3
);  ̇      and  ̇     are the 
volumetric flow rates of shell and core phases (cm
3
/hour);  ̇      is the total volumetric 
flow rate of polymer (cm
3
/hour);  ̇  is the total production rate of microspheres (1/hour); 
  is the measured mean outer diameter of DWMS (µm);       is the calculated core 
diameter; and     is the calculated shell thickness of DWMS (µm). The densities of the 
polymers were assumed to be     =1.34 g/cm
3
,     =1.24 g/cm
3
. 
 Despite changing solvents and polymer molecular weights, the diameters of 
uniform DWMS were ~55 µm, and all sample average diameters were within 2 µm of 
each other (Table 3.2, Figure 3.2). Based on the measured outer diameter of DWMS, the 
core diameter as well as the shell thickness was calculated for DWMS (Table 3.2). In all 
cases, the shell thickness was ~10 µm and PLG core diameter was ~35 µm. Thus, PLG 
SWMS in DCM at aimed diameter of ~35 µm were fabricated as a control.  
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Figure 3. 1: Size distributions of PLA(PLG) DWMS formed with different solvent configurations: (A) 
DCM(DCM); (B) EtAc(DCM); (C) DCM(EtAc); (D) EtAc(EtAc). 
 
 BSA loading and encapsulation efficiency of EtAc(DCM) DWMS A1, A2, B1, 
B2 and B3 were in general higher than DCM(DCM) DWMS C1 and C2, but not C3 
(Figure 3.3). This is likely due to faster extraction of the shell solvent, EtAc [36], which 
results in a polymer-rich shell preventing loss of BSA from the particle core. When DCM 
was used as shell solvent, the slower removal of DCM from both shell and core may 
allow BSA transport toward the particle surface. 
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Table 3. 2: Dimensions of DWMS/SWMS 
Sample Solvent Selection 
Shell(Core) 
PLA 
Shell Mw (kDa) 
 
PLG core Mw 
(kDa) 
Outer Diameter 
Measured (μm) 
Core Diameter 
Calculated (μm) 
Shell Thickness 
Calculated (μm) 
A1 EtAc(DCM) 43 4.2 55.1±2.0 35.8 9.7 
A2 EtAc(DCM) 106 4.2 56.8±2.8 36.9 10.0 
N/A
a 
EtAc(DCM) 192 4.2 N/A N/A N/A 
B1 EtAc(DCM) 38 4.2 56.4±2.4 36.7 9.9 
B2 EtAc(DCM) 38 15 55.5±2.0 36.1 9.7 
B3 EtAc(DCM) 38 38 55.0±1.6 35.7 9.6 
C1 DCM(DCM) 43 4.2 54.8±1.4 35.6 9.6 
C2 DCM(DCM) 106 4.2 55.4±1.7 36.0 9.7 
C3 DCM(DCM) 192 4.2 56.6±2.1 36.8 9.9 
O (DCM) N/A 4.2 35.2 ±1.0 35.2 0 
                           a
PLA Mw=192 kDa’s chirality changed from poly(D,L-lactide) to poly(L-lactide) and cannot dissolved in EtAc
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Figure 3. 2: Size distributions of DWMS and SWMS: (O), (DCM) SWMS, PLG Mw 4.2 kDa; (A1), EtAc(DCM) DWMS, PLA Mw 43 kDa, PLG Mw 4.2 kDa; 
(A2), EtAc(DCM) DWMS, PLA Mw 106 kDa, PLG Mw 4.2 kDa; (B1), EtAc(DCM) DWMS, PLA Mw 38 kDa, PLG Mw 4.2 kDa; (B2), EtAc(DCM) DWMS, 
PLA Mw 38 kDa, PLG Mw 15 kDa; (B3), EtAc(DCM) DWMS, PLA Mw 38 kDa, PLG Mw 38 kDa; (C1), DCM(DCM) DWMS, PLA Mw 43 kDa, PLG Mw 
4.2 kDa; (C2), DCM(DCM) DWMS, PLA Mw 106 kDa, PLG Mw 4.2 kDa, (C3), DCM(DCM) DWMS, PLA Mw 192 kDa, PLG Mw 4.2 kDa. 
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Figure 3. 3: BSA loading (A) and encapsulation efficiency (B) of DWMS/SWMS: (A1) EtAc(DCM), PLG 
Mw 4.2 kDa and PLA Mw 43 kDa; (A2) EtAc(DCM), PLG Mw 4.2 kDa and PLA Mw 106 kDa; (B1) 
EtAc(DCM), PLG Mw 4.2 kDa and PLA Mw 38 kDa; (B2) EtAc(DCM), PLG Mw 15 kDa and PLA Mw 
38 kDa; (B3) EtAc(DCM), PLG Mw 38 kDa and PLA Mw 38 kDa; (C1) DCM(DCM), PLG Mw 4.2 kDa 
and PLA Mw 43 kDa; (C2) DCM(DCM), PLG Mw 4.2 kDa and PLA Mw 106 kDa; (C3) DCM(DCM), 
PLG Mw 4.2 kDa and PLA Mw 192 kDa; (O) (DCM), PLG Mw 4.2 Da. 
 
 In general, BSA encapsulation efficiency increased with the shell polymer 
molecular weight. For sample C3, which contained 192 kDa PLA shell, the chirality 
changed from poly(D,L-lactide) to poly(L-lactide), and the BSA loading and 
encapsulation efficiency increased dramatically compared to C1 and C2. The increase in 
BSA loading and encapsulation efficiency with PLA molecular weight may be explained 
by increased PLA hydrophobicity, thus increased solution viscosity, which could better 
confine the BSA/water phase of the emulsion in the PLG core region. In addition, the 
higher molecular weight PLA would be expected to harden faster, and thus more 
BSA/water phase of the emulsion could be trapped within PLG cores [37]. Increasing 
core PLG molecular weight (samples B1, B2 and B3, respectively) decreased the loading 
and encapsulation efficiency.  
 For sample O, SWMS comprising 4.2 kDa PLG, which were produced to mimic 
the PLG cores of DWMS, the loading was higher than all DWMS because there was no 
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drug-free PLA layer, yet the encapsulation efficiency of single-wall microspheres was 
lower than all DWMS. The lack of a shell layer may lead to easier transport and escape of 
BSA out of the microspheres.  
3.3.2 BSA In Vitro Release 
The release of BSA from polymer microparticles is expected to be controlled by a 
combination of particle size, initial BSA distribution, polymer degradation rates and other 
factors such as architecture of the microparticles and pore formation during degradation. 
We investigated the release of BSA from DWMS formed with EtAc(DCM) and 
DCM(DCM) solvent configurations and of varying PLG core and PLA shell molecular 
weights. BSA cumulative percent release profiles were obtained relative to the initial 
protein loading of DWMS/SWMS (Figure 3.4A, C and E). The final release amount 
reached from 100%-130% of initial loading. Release greater than 100% was probably due 
to under-estimation of the initial loading caused by incomplete extraction of BSA. In 
order to better compare different BSA profiles, normalized cumulative fraction release 
profiles were generated using cumulative percent release profiles normalized to final 
release amount of BSA (Figure 3.4B, D and E). In general, all samples exhibited a tri-
phasic release: an initial rapid release, a lag phase and a final steady release. Release 
from samples A1 and A2, prepared with EtAc(DCM) solvent configuration, low 
molecular weight PLG core (4.2 kDa), and differing PLA shell molecular weights, were 
almost identical (Figure 3.4B). Compared to SWMS of the same size as the PLG core in 
A1 and A2, sample O, the lag phase and the final steady release phase were delayed in 
samples A1 and A2; for sample O, complete release occurred at around 55 days, while 
for A1 and A2, complete release was delayed to 70 days. Also, the BSA release rates 
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from particles A1 and A2 in the steady release phase were slower than that of O. These 
release profiles showed that the presence of the drug-free PLA shell postponed the BSA 
release rate from the PLG core, but the molecular weight of the PLA shell (43 kDa for A1, 
106 kDa for A2) had no influence. This probably was due to the slow degradation rate of 
PLA compared to PLG. Even at molecular weight of 43 kDa, the degradation was too 
slow to be discernible from molecular weight 106 kDa over 90 days.  
 Increasing molecular weight of the PLG core had an interesting effect on BSA 
release rates (Figure 3.4D).  Release from DWMS with low molecular weight PLG core 
(B1) was similar to SWMS (O) with an initial release of approximately 40% loading in 
10 days and a 10 day lag phase before the final steady release. However, as the core PLG 
molecular weight increased the overall release rate increased dramatically. In B2 and B3, 
90% of the BSA was released in less than 30 days. 
 For DCM(DCM) DWMS, BSA release from C1 and C2 particles was similar 
despite the varying molecular weight of the PLA shell and was relatively fast compared 
to SWMS.  For sample C3, however, the release rate was much slower probably due to 
the very slow degradation and presumed crystallinity of the high molecular weight 
poly(L-lactide) shell (Figure 3.4F). 
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Figure 3. 4: In vitro release profiles of BSA from DWMS/SWMS: (A), (B)  Sample A1, A2, O; (C), (D) 
Sample B1, B2, B3, O; (E), (F) Sample C1, C2, C3, O. (A1) EtAc(DCM), PLG Mw 4.2 kDa and PLA Mw 
43 kDa; (A2) EtAc(DCM), PLG Mw 4.2 kDa and PLA Mw 106 kDa; (B1) EtAc(DCM), PLG Mw 4.2 kDa 
and PLA Mw 38 kDa; (B2) EtAc(DCM), PLG Mw 15 kDa and PLA Mw 38 kDa; (B3) EtAc(DCM), PLG 
Mw 38 kDa and PLA Mw 38 kDa; (C1) DCM(DCM), PLG Mw 4.2 kDa and PLA Mw 43 kDa; (C2) 
DCM(DCM), PLG Mw 4.2 kDa and PLA Mw 106 kDa; (C3) DCM(DCM), PLG Mw 4.2 kDa and PLA 
Mw 192 kDa; (O) (DCM), PLG Mw 4.2 Da. 
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3.3.3 BSA Distribution in DWMS and SWMS 
Confocal fluorescence microscopy allowed visualization of the spatial distribution of 
TAMRA-labeled BSA within SWMS and DWMS (Figure 3.5). TAMRA-BSA 
distribution within sample O, SWMS mimicking the low molecular weight (4.2 kDa) 
PLG core, was relatively even across the microspheres, as expected. For EtAc(DCM) 
DWMS with low molecular weight PLG cores, A1, A2 and B1, the TAMRA-BSA 
fluorescence was concentrated in the core area and drug-free regions near the particle 
surface were observed. For B2 and B3 comprising EtAc(DCM) DWMS with higher PLG 
molecular weight, although B3 showed the relatively concentrated BSA region, the 
fluorescence intensity was relatively low, while in B2 the TAMRA-BSA spread 
throughout the whole microparticles. In DCM(DCM) DWMS, samples C1-C3, TAMRA-
BSA was not confined in a concentrated core; instead, the protein appeared to spread 
throughout the microspheres and tended to be concentrated near the surface.  
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Figure 3. 5: Confocal fluorescence micrographs (for each pair, left: fluorescence; right: merged 
fluorescence and transmitted light) of BSA-loaded SWMS and DWMS: of BSA-loaded SWMS and 
DWMS: Sample O, (DCM), PLG Mw 4.2 kDa; Sample A1, EtAc(DCM), PLG Mw 4.2 kDa and PLA Mw 
43 kDa; Sample A2, EtAc(DCM), PLG Mw 4.2 kDa and PLA Mw 106 kDa; Sample B1, EtAc(DCM), PLG 
Mw 4.2 kDa and PLA Mw 38 kDa; Sample B2, EtAc(DCM), PLG Mw 15 kDa and PLA Mw 38 kDa; 
Sample B3, EtAc(DCM), PLG Mw 38 kDa and PLA Mw 38 kDa; Sample C1, DCM(DCM), PLG Mw 4.2 
kDa and PLA Mw 43 kDa; Sample C2, DCM(DCM), PLG Mw 4.2 kDa and PLA Mw 106 kDa; Sample C3, 
DCM(DCM), PLG Mw 4.2 kDa and PLA Mw 192 kDa. 
 
 Image analysis of TAMRA-BSA distribution within microparticles using ImageJ 
provided the average radial fluorescence intensities of DWMS and SWMS (Figure 3.6). 
The BSA was relatively evenly distributed in SWMS as expected (sample O). The 
intensities of samples A1, A2, and B1, with EtAc(DCM) solvent configuration and low 
PLG molecular weight (4.2 kDa) but PLA molecular weight of 43 kDa, 106 kDa to 38 
kDa, respectively, all exhibit high fluorescence intensity within 20 µm of the particle 
center, which gradually diminishes closer to the surface. These data together confirm that 
the BSA loaded in DWMS was concentrated in the ~35 µm porous core areas surrounded 
by an ~10 µm dense PLA shell. Further, the 10 µm PLA shell increased the BSA loading 
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and encapsulation efficiency (Figure 3.3A and B) as well as generating a delay of BSA in 
vitro release over three months (Figure 3.4B and D). Samples B2 and B3 with 
EtAc(DCM) solvent configuration and high molecular weight (15 kDa, 38 kDa) PLG, 
exhibited different fluorescence distributions. BSA distributed more evenly across the 
whole diameter of B2 particles (Figure 3.5). This result suggests that higher molecular 
weight PLG “pushes” BSA from the core to the surface due to the more hydrophobic 
nature of the higher molecular weight PLG. The relatively fast release of BSA from these 
particles is also consistent with a more uniform BSA distribution. For sample B3, the 
intensity of TAMRA-BSA fluorescence was relatively low but was localized largely to 
the particle core (Figure 3.5). The combination of lower loading and relatively uniform 
BSA distribution leads to fast release of BSA in vitro. The high molecular weight PLG 
core DMWS also exhibited lower BSA encapsulation efficiency due to their 
hydrophobicity. For DCM(DCM) solvent configuration, all micrographs showed higher 
intensity near the surface and lower intensity near the center of the particles. This is most 
likely due to slow removal of DCM from the core and shell, allowing BSA/water droplets 
to coalesce and migrate towards the particle surfaces. Loading and encapsulation 
efficiency were also lower than EtAc(DCM) DWMS. 
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Figure 3. 6: Average fluorescence intensities of TAMRA-labeled BSA along radial direction of 
microparticles: Sample O, SWMS (DCM), PLG Mw 4.2 kDa; Sample A1, DWMS EtAc(DCM) PLG Mw 
4.2 kDa, PLA Mw 43 kDa; Sample A2, DWMS EtAc(DCM), PLG Mw 4.2 kDa, PLA Mw 106 kDa; 
Sample B1, DWMS EtAc(DCM), PLG Mw 4.2 kDa, PLA Mw 38 kDa; Sample B2, DWMS EtAc(DCM), 
PLG Mw 15 kDa, PLA Mw 38 kDa; Sample B3, DWMS EtAc(DCM), PLG Mw 38 kDa, PLA Mw 38 kDa; 
Sample C1, DWMS DCM(DCM), PLG Mw 4.2 kDa, PLA Mw 43 kDa Sample C2, DWMS DCM(DCM), 
PLG Mw 4.2 kDa, PLA Mw 106 kDa; Sample C3, DWMS DCM(DCM), PLG Mw 4.2 kDa, PLA Mw 192 
kDa. 
 
3.3.4 DWMS Thermal Properties 
Thermo-chemical properties are an important factor for polymer degradation and drug 
release. In general, high glass transition temperature (Tg) and/or high degree of 
crystallinity reduce degradation rates of PLG and PLA. DWMS as well as pure PLG and 
PLA were examined using DSC to determine the Tg and Tm. For EtAc(DCM) DWMS 
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(Sample A1, A2, B1-B3), the DSC showed a combination of PLA and PLG Tg peaks 
centered at 50, 53, 51 ºC for PLA Mw 38, 43, 106 kDa and  37, 46, 47 ºC for PLG Mw 
4.2, 15, 38 kDa, respectively (Figure 3.7A-E). Since Tg was a relatively weak signal 
compared to Tm, the DWMS Tg peaks were noisy and relatively broad. There was no Tm 
for DWMS A1, A2, and B1-B3, indicating that PLG and PLA in those microparticles 
were all amorphous. For DCM(DCM) DWMS C1 and C2, PLG and PLA were also 
amorphous. However, the Tg appeared very sharp in the PLA Tg region or even shifted to 
a higher temperature For C1, Tg peaks shifted to 54 ºC while PLA Tg peak centered at 53 
ºC. For C2, Tg peaks shifted to 55 ºC while PLA Tg peak centered at 51 ºC. These sharp 
peaks may be due to the mixing of PLG and PLA in these DWMS (Figure 3.7F, G). For 
C3 and PLA Mw 192 kDa, strong Tm signals were observed at 174 ºC due to the 
crystallinity of PLA (Figure 3.7H). 
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Figure 3. 7: DSC graphs of DWMS, pure PLA and PLG with different molecular weight.   
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3.3.5 Particle Morphology during In Vitro DWMS/SWMS Degradation/Erosion 
DWMS were incubated in PBS at 37 ºC for a period of three months and samples were 
removed periodically for visualization by SEM.  At day 0, small pores were apparent on 
the surface of A1 and A2, which were probably caused by EtAc extraction. Large 
concave indentions were observed on the surfaces of A2, which might be caused by the 
dense PLA shell collapsing toward the porous PLG inner core during particle hardening. 
The cores of A1 and A2 were clearly porous, which is in accordance with confocal 
images showing BSA/water droplets concentrate in the relatively hydrophilic, low 
molecular weight PLG (4.2 kDa). The less porous PLA shell areas were approximately 
10 µm thick as calculated (Table 3.2). A1 and A2 developed surface pores as degradation 
progressed.  A2 appeared to degrade slower than A1, as A1 particles developed holes in 
the surfaces by day 42 and cracked by day 63, while A2 still exhibited an intact spherical 
shape. This was probably due to the higher molecular weight of PLA (106 kDa compared 
to 43 kDa) in A2 shell phase. Both A1 and A2 developed hollow cores by day 21, and the 
hollow region grew larger through day 63. As the hollow cores gradually became larger, 
the shells became thinner and finally the DWMS lost their particle morphology and 
appeared to break into pieces (Figure 3.8).  
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Figure 3. 8: SEM images of A1, A2 degradation/erosion study. Sample A1, EtAc(DCM), PLG Mw 4.2 kDa 
and PLA Mw 43 kDa; Sample A2, EtAc(DCM), PLG Mw 4.2 kDa and PLA Mw 106 kDa. 
  
 At day 0, B1 exhibited smooth surfaces, porous cores and dense shell regions 
similar to A1 and A2. However, for B2 and B3 containing higher molecular weight PLG, 
the porous structures extend to closer to the surface and the interiors showed no clearly 
distinct porous cores and less porous shell regions. The surfaces of sample B1 became 
rough and porous as degradation progressed and exhibited a hollow core area from day 
21. For samples B2 and B3, significant surface porosity did not appear until between day 
21 and day 42 and decreased from day 42 to day 63. Further, hollow cores were not 
obvious until day 42, likely because the higher molecular weight of PLG cores in B2 and 
B3 degraded slower than those with low molecular weight in A1, A2 and B1 (Figure 3.9).  
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Figure 3. 9: SEM images of B1, B2 and B3 degradation/erosion study. Sample B1, EtAc(DCM), PLG Mw 
4.2 kDa and PLA Mw 38 kDa; Sample B2, EtAc(DCM), PLG Mw 15 kDa and PLA Mw 38 kDa; Sample 
B3, EtAc(DCM), PLG Mw 38 kDa and PLA Mw 38 kDa. 
 
 The surfaces of DCM(DCM) particles C1-C3 were much more porous than A1-
A2 and B1-B3 at Day 0. No clearly defined core and shell regions could be identified. 
This probably was because the slower removal of DCM from both shell and core areas 
would allow the BSA/water domains to redistribute throughout the microspheres. The 
encapsulation and confinement of the BSA-PLG core were poor compared to EtAc(DCM) 
solvent configuration.  Significant surface porosity was observed after day 21 for C1-C3. 
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Erosion rates of C1, C2 and C3 decreased with increasing PLA molecular weight. C1 lost 
particle morphology by day 90 while C2 and C3 appeared intact at day 90. For C1 and C2 
no noticeable hollow core regions formed until day 63. For C3, due to the high molecular 
weight and crystallinity of PLA and poorly concentrated BSA cores, no hollow core areas 
were observed throughout three months (Figure 3.10). 
 
Figure 3. 10: SEM images of C1, C2 and C3 degradation study. Sample C1, DCM(DCM), PLG Mw 4.2 
kDa and PLA Mw 43 kDa; Sample C2, DCM(DCM), PLG Mw 4.2 kDa and PLA Mw 106 kDa; Sample C3, 
DCM(DCM), PLG Mw 4.2 kDa and PLA Mw 192 kDa. 
 
62 
 
 For SWMS O, since there was no protecting PLA shell, particle degradation was 
relatively fast compared to DWMS. The cross-section revealed an evenly distributed 
porous structure due to the BSA emulsion. This result agreed with previous confocal 
fluorescence images of SWMS. The microspheres quickly lost spherical integrity by day 
21 (Figure 3.11).  
 
 Figure 3. 11: SEM images of SWMS O ((DCM), PLG Mw 4.2 kDa) degradation study 
 
3.4 Discussion 
Core-shell DWMS provide a more complex delivery system than SWMS with more 
flexibility to achieve desired properties and release profiles. By using a precision particle 
fabrication technique, we were able to produce uniform double-wall and single-wall 
microspheres with control of polymer and drug localization in the core or shell, uniform 
overall diameter and shell thickness. In particular, by choosing appropriate fabrication 
parameters, PPF can produce DWMS comprising PLA and PLG as the shell and core 
phase, respectively, with BSA loaded within the PLG core. By using solvent 
configuration of EtAc(DCM) and DCM(DCM), monodisperse DWMS were fabricated 
with overall diameters (~55 µm) within 2 µm. Because the calculated core diameters of 
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DWMS were around 35 µm, SWMS with a diameter of 35 µm were also produced. Thus, 
we have excluded the influence of differing particle sizes and structure on the release of 
BSA and can elucidate the impact of BSA initial distribution and polymer 
degradation/erosion on the final BSA release rate. 
 An initial “burst” is commonly observed upon release of small water-soluble 
molecules and macromolecules from PLG microparticles, in which a significant amount 
of drug is released in a short time. This “burst” has often been ascribed to desorption of 
drug that may have localized to the particle surface or adsorbed during the encapsulation 
process or to rapid diffusion of the drug though initial pores connected to the particle 
surface. From the release data, surface SEM images and confocal fluorescence 
micrographs, the fast release of BSA in DCM(DCM) DWMS can be attributed to initial 
BSA distribution near the periphery and high porosity of particles.  
 Besides particle size, architecture and initial drug distribution, polymer 
degradation/erosion is another important factor influencing protein release. Degradation 
is the act of individual polymer chain cleavage while erosion is mass loss from the 
overall polymer matrix. Since BSA is relatively large and hydrophilic, diffusion through 
the polymer matrix is expected to be negligible. Rather, protein is most likely released 
from the particles by diffusion through water-filled pores and holes formed during 
degradation/erosion. For PLG and PLA, both of which are bulk eroding polymers, 
degradation takes place throughout the entire polymer matrix simultaneously. Water 
diffuses into the polymer, inducing swelling and bond cleavage throughout. Upon 
increasing the molecular weight of PLG and PLA, the hydrophobicity also increased and 
the degradation/erosion rate decreased. For two groups of samples A1 (EtAc(DCM), PLG 
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Mw 4.2 kDa, PLA Mw 43kDa), A2 (EtAc(DCM), PLG Mw 4.2 kDa, PLA Mw 106 kDa) 
and C1 (DCM(DCM), PLG Mw 4.2 kDa, PLA Mw 43 kDa), C2 (DCM(DCM), PLG Mw 
4.2 kDa, PLA Mw 43 kDa), both of which possess similar particle size, shell thickness 
and initial BSA distribution, increasing PLA molecular weight while keeping PLG 
molecular weight constant had relatively no effect on the final BSA in vitro release rate 
(Figure 3.4B and F). This result might result from the compromised spherical shape of 
A2 and the peripheral BSA distribution of C2, both of which lead to faster release of 
BSA although the degradation/erosion rate of the shell polymer is relatively low. For 
samples B1 (EtAc(DCM), PLG Mw 4.2 kDa, PLA Mw 38 kDa) and C3 (DCM(DCM), 
PLG Mw 4.2 kDa, PLA Mw 192 kDa) compared to A1, A2, C1 and C2, decreasing or 
increasing PLA molecular weight resulted in faster and slower BSA release, as expected. 
3.5 Conclusions 
In this study, monodisperse double-wall microspheres as well as monolithic single-wall 
microspheres were fabricated using precision particle fabrication technology to exclude 
size and structure interferences on protein release rate. DCM(DCM) as well as 
EtAc(DCM) solvent configurations resulted in good DWMS uniformity. Due to the fast 
hardening rate of EtAc compared to DCM in the shell, EtAc(DCM) DWMS better 
encapsulated protein-loaded PLG core, and thus generally produced higher protein 
loading and encapsulation efficiency than DCM(DCM) counterparts. The molecular 
weight of core PLG and shell PLA, together with solvent configuration, influence depot 
degradation rate, protein distribution and in vitro release. EtAc(DCM) DWMS with lower 
PLG molecular weight (4.2 kDa) and relatively lower PLA molecular weight (43 kDa) 
can form spherical DWMS with clear core-shell structures, exhibiting porous protein–
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encapsulating cores, less porous drug-free shell and can postpone the protein in vitro 
release compared to SWMS. Increasing core PLG molecular weight resulted in relatively 
uniform distribution of protein and faster in vitro release than SWMS. Due to the slow 
particle hardening process, DCM(DCM) DWMS of different PLA molecular weight 
exhibited protein localized near the surface and fast protein in vitro release except Mw 
192 kDa PLA(PLLA), which degraded much more slowly due to its crystallinity. 
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Chapter 4. Uniform DWMS of Controllable Shell Thickness for Protein Delivery  
4.1 Introduction 
Advances in biotechnology have led to an explosion of therapeutic proteins as potential 
drug candidates [1]. However, due to their macromolecular size and short half-lives in 
vivo, the administration routes of protein drugs are limited. In order to maintain effective 
drug concentration, frequent injections are typically needed, which may lead to poor 
patient compliance. Thus, well-controlled and sustained delivery methods are crucial for 
the application of protein therapeutics, and the development of effective delivery systems 
is required to turn biological potential into medical reality.  
 Biodegradable polymer-based delivery systems administered by oral, pulmonary 
or parenteral injection bear advantages such as reduced dosing frequency, high local drug 
concentrations at the site of administration, protection of fragile therapeutics, minimized 
side effects, simple production process and no requirement for surgical resection. In 
particular, biodegradable polymer microparticles have received much attention, and 
several products have been commercialized. 
 Desirable drug release profiles may be achieved with monolithic single-wall 
microspheres (SWMS) by choosing polymers with appropriate degradation kinetics [2], 
varying physical characteristics of particles [3-7], conjugating drugs to polymers [8] or 
controlling the particle size distribution [9-16]. However, the control is limited due to 
their simple structures. Adding another drug-free polymer layer of variable thickness as a 
rate-controlling membrane provides more flexibility in acquiring desired release rates as 
well as improves encapsulation of the protein drugs.  
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 In this chapter, we report the first example of monodisperse double-wall 
microspheres (DWMS) comprising a protein-encapsulating poly(lactide-co-glycolide) 
(PLG) core and highly uniform, drug-free poly(lactic acid) (PLA) shell as the release 
rate-controlling layer by using precision particle fabrication technique (PPF) [17-21]. 
From conclusions of previous Chapter 3, PLG molecular weight 4.2 kDa and PLA 
molecular weight 43 kDa were chosen. Bovine serum albumin (BSA) was used as a 
model protein.  In particular, monodisperse DWMS were produced with constant-sized 
BSA-containing PLG cores and PLA shell with different thickness. Also, monodisperse 
PLG SWMS loaded with BSA, mimicking the PLG core in DWMS, were fabricated for 
comparison. Most importantly, in vitro BSA release was quantified over a period of five 
months to determine the effect of uniform shell thickness on protein release rates. In 
addition, observation of DWMS erosion provides insight into the mechanism of BSA 
release. 
4.2 Materials and Methods 
4.2.1 Materials 
Poly(D,L-lactide-co-glycolide)  (PLG, 50:50 lactide:glycolide ratio, Mw 4.2 kDa) and 
poly(D,L-lactic acid) (PLA, Mw 43 kDa) were purchased from LACTEL Absorbable 
Polymers. Bovine serum albumin (BSA, Mw 66,700 Da) and reagent grade sodium 
bicarbonate were purchased from Fisher Scientific. Chromatography grade of dimethyl 
sulfoxide (DMSO), ethyl acetate (EtAc) and dichloromethane (DCM) were obtained from 
Sigma-Aldrich. Fluorescent dye 5-(and-6)-carboxytetramethylrhodamine succinimidyl 
ester (TAMRA) was obtained from Molecular Probes. Poly(vinyl alcohol) (PVA, Mw 
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25,000 Da, 88% hydrolyzed) was purchased from Polysciences. Tween 80 was purchased 
from Acros Organics.  
4.2.2 Fabrication of DWMS with Controlled Shell Thickness 
Triple nozzle and double nozzle systems were employed for producing DWMS and 
SWMS, respectively (Figure 2.1, Figure 2.2). For the triple nozzle system, a steel 
hypodermic needle (PrecisionGlide, Becton Dickinson Co.) with flat tip was used as the 
innermost nozzle, which was surrounded coaxially by the inner glass nozzle made from a 
glass capillary (World Precision Instrument, Inc.). The outer glass nozzle surrounded the 
inner glass nozzle and was made of Pyrex glass (Kimax). For the double nozzle system, 
no outer glass nozzle was used.  
 The core phase containing BSA (100 mg/mL in water) was emulsified with 
PLG/DCM solution (30% w/v) at a volumetric ratio of 1:10 using Ultrasonic tip (CE 
Converter 102 C, Branson) at 60% amplitude for 1 minute. By keeping flow rates the 
same and varying the shell phase PLA concentration (3% w/v, 6% w/v, 9% w/v) while 
keeping the core phase PLG concentration constant (30% w/v), DWMS with different 
shell thickness were fabricated with different PLA/PLG mass ratio. PVA water solution 
(0.5% w/v) was used as non-solvent carrier stream.  
 For DWMS fabrication, two syringe pumps (Pump 11, Harvard Apparatus) were 
employed for carrying the core and shell phase. One gear pump (IP65, ISMATEC) was 
used for PVA carrier stream. The core phase PLG/BSA emulsion stream passed through 
the innermost metal nozzle and the shell phase PLA stream passed through the inner glass 
nozzle. The outer glass nozzle was for PVA non-solvent carrier stream, which was used 
to improve the round shape of particles as well as providing “drag force” in order to 
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produce particles smaller than the nozzle opening [13, 14]. For SWMS fabrication, only 
one syringe pump was used for the PLG/BSA emulsion stream. This core phase passed 
through the innermost metal nozzle and the inner glass nozzle was used for carrier stream 
which was pumped by the gear pump. The fabrication of SWMS was based on the results 
of DWMS fabrication. The outer diameters of SWMS were equal to the calculated core 
diameters of DWMS. The frequency generator (Agilent 33220A) and piezoelectric 
transducer (CV33, Sonic & Materials Inc.) of PPF system generated an acoustic wave on 
the nozzle to break the polymer-based stream into uniform droplets with desired outer 
diameter. Nascent DWMS and SWMS (wet particles before lyophilizing) were collected 
in a beaker with 500 mL of 0.5% (w/v) PVA solution and were stirred for another 3 h for 
organic solvent extraction/evaporation. The particles were filtered (Filter Paper #4, 
Whatman), washed three times by deionized water and lyophilized for 48 h. Samples 
were stored until use in a -20 
o
C freezer with desiccant. 
4.2.3 Particle Size Distribution 
The size distributions of nascent DWMS and SWMS were determined using a Coulter 
Multisizer III (Beckman Coulter Inc.) with a 200 micron aperture. More than 10,000 
particles were measured for each sample. 
4.2.4 Protein Loading and Encapsulation Efficiency 
To measure the BSA loading of each batch of microparticles, a sample of approximately 
5 mg microparticles was dissolved in 100 µL DMSO. After complete dissolution, the 
solution was added dropwise into 1 mL of phosphate-buffered saline (PBS, pH 7.4±0.05) 
and then incubated for 1 h at 37 
o
C with shaking (240 rpm). The mixture was centrifuged 
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for 10 minutes at 10,000 rpm to pellet the precipitate. BSA concentration in the 
supernatant was determined using BCA assay (Pierce). All absorbance measurements 
were taken on a SpectraMax 340 PC reader equipped with SoFTMax Pro software. The 
loading of each batch equaled the mass of BSA measured by absorbance per mass of 
particles. The encapsulation efficiency of each batch of microparticles equaled the actual 
loading divided by theoretical BSA loading multiplied by 100. 
4.2.5 BSA In Vitro Release 
For each batch of DWMS or SWMS, a sample of approximately 30 mg was suspended in 
1.25 mL release buffer consisting of PBS and 0.05% (v/v) Tween 80. These samples 
were incubated for three to five months at 37 
o
C with shaking (240 rpm). At various time 
points, the microparticles were centrifuges at 10,000 rpm for 10min, and 1.0 mL 
supernatant was removed and replaced with fresh media in order to maintain constant pH 
sink condition. The release study was performed in triplicate, and BSA concentrations in 
the collected supernatants were measured using BCA assay (Pierce).  
4.2.6 Confocal Fluorescence Microscopy 
Twenty milligrams of BSA were dissolved in 2 mL of sodium bicarbonate (Fisher) at pH 
8.3±0.05. A solution of 1 mg TAMRA in 100 µL DMSO (Fisher) was then pipetted into a 
foil-wrapped vial containing the BSA solution. The solution was stirred for 60-120 
minutes at room temperature, and then separated using PD-10 desalting column (GE 
Healthcare). The labeled protein was collected from the column, frozen, and lyophilized. 
The degree of labeling (DoL, the number of TAMRA molecules attached to each protein 
molecule) as determined from the relative absorbances of TAMRA (555 nm) and BSA 
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(280 nm) was 3.40. Particles were loaded with 5% of TAMRA-labeled BSA and 95% 
unlabeled BSA. 
 Fluorescent and transmitted light images of the protein-loaded DWMS and 
SWMS were taken with a Leica SP2 visible laser confocal microscope. Images were 
obtained with a 63x oil immersion lens. Fluorescence was excited using a HeNe laser 
(543 nm) and emission collected with a 575-640 nm band-pass filter. 
4.2.7 Particle DSC Study 
Differential Scanning Calorimetry (DSC) was performed on each batch of microparticles 
as well as pure polymers to study their thermal properties such as glass transition 
temperatures (Tg) and melting temperature (Tm). Perkin Elmer Pyris Diamond DSC was 
used, and all samples were heated from -10 
o
C to 200 
o
C at 10 
o
C/min. 
4.2.8 Scanning Electron Microscopy (SEM) 
DWMS and SWMS were prepared for imaging by placing a droplet of an aqueous 
particle suspension on a silicon stub. The samples were dried overnight and sputter 
coated with gold and platinum prior to imaging. In order to image the cross-sections, 
microspheres were frozen in liquid nitrogen and fractured using a razor blade on a glass 
slide, resuspended in a water droplet, and mounted on silicon stubs. The JEOL 6060 LV 
scanning electron microscope was used at an acceleration voltage of 5-20 kV. 
4.2.9 Particle Degradation/Erosion Study 
For each batch of DWMS or SWMS, a sample of approximately 5 mg was suspended in 
1.25 mL release buffer consisting of 0.05% (v/v) Tween 80 and PBS. These samples 
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were incubated at 37 
o
C with shaking (240 rpm). At various time points, all supernatant 
was removed and the samples were frozen and lyophilized for at least 48 h. The samples 
were prepared for SEM as described above. 
4.2.10 SDS-PAGE 
BSA in supernatants during in vitro release was subjected to non-reduced sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis using precast gradient 
gels (4-20% Tris-HCl/glycine) and Mini-PROTEAN II system (Bio-Rad Laboratories, 
Inc.). Running buffer (25 mM Tris, 192 mM glycine and 0.1% (w/v) SDS, pH 8.3) were 
diluted from 10x Tris/Glycine/SDS buffer. Samples were diluted 1:1 in Laemmli sample 
buffer (62.5 mM Tris-HCl, pH 6.8, 25% glycerol, 2% SDS, 0.01% Bromophenol blue) 
under non-reduced conditions (without β-mercaptoethanol or DTT), and heated for 1 min 
at 95 
o
C prior to loading. Gels were electrophoresed for 40 min at 200 V and then stained 
with Coomassie blue to visualize the protein bands.  
4.3 Results 
4.3.1 Production of BSA-loaded DWMS with Different Shell Thickness 
Organic solvents DCM and EtAc are commonly used for dissolving biodegradable 
polymers [22-25]. For DWMS, we can choose different configurations of DCM and EtAc 
to dissolve the core polymer (PLG) and shell polymer (PLA). From Chapter 3, DWMS 
fabricated with PPF using DCM as shell solvent and EtAc as core solvent (designated as 
DCM(EtAc)) or EtAc as both shell and core solvents (EtAc(EtAc)) have poor uniformity 
(Figure 3.1C, D). EtAc(DCM) and DCM(DCM) configurations could generate DWMS 
with good uniformity. 
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 We produced DCM(DCM) and EtAc(DCM) DWMS with different shell thickness 
by keeping PLA shell and PLG core flow rates constant and increasing PLA 
concentration in the shell phase from 3% to 9% (w/v), thus increasing the PLA/PLG mass 
ratio. Assuming no polymer mass loss, volume additivity and ideal concentric core-shell 
structure of DWMS, the PLG core diameters and PLA shell thickness can be calculated 
from the measured overall particle diameter (Equation (3.1)-(3.6), Table 4.1).  
 
Table 4. 1: Dimensions of DWMS/SWMS with different shell thickness 
Sample Solvent 
Selection 
Shell (Core) 
PLA (PLG) 
conc. w/v 
PLA/PLG 
mass ratio 
Outer Diameter 
Measured (μm) 
Core Diameter 
Calculated 
(μm) 
Shell 
Thickness 
Calculated 
(μm) 
A1 DCM(DCM) 3% (30%) 1.09 61.32±1.35 48.57 6.37 
A2 DCM(DCM) 6% (30%) 2.14 71.12±1.31 49.42 10.85 
A3 DCM(DCM) 9% (30%) 3.04 76.75±1.26 48.73 14.01 
B1 EtAc(DCM) 3% (30%) 1.09 60.47±2.18 47.90 6.28 
B2 EtAc(DCM) 6% (30%) 2.14 69.77±1.57 48.48 10.64 
B3 EtAc(DCM) 9% (30%) 3.04 76.32±1.90 48.45 13.93 
O (DCM) (30%) 0 48.48±1.04 N/A
a 
N/A
a 
a
 Not applicable 
 
 DWMS fabricated using both DCM(DCM) and EtAc(DCM) solvent 
configurations had good uniformity (Figure 4.1). For a given PLA/PLG mass ratio, 
particles exhibited similar outer diameter, within 2 µm, regardless of solvent selection 
(Table 4.1). The calculated diameter of PLG core and the PLA shell thickness are also 
close. The calculated PLG core diameter was constant at 48-50 µm, and the shell 
thickness increased from ~6 µm to ~14 µm upon increasing the PLA/PLG mass ratio 
from 1.09 to 3.04 (Table 4.1). When increasing PLA concentration in DCM or EtAc to 12% 
(w/v) or higher, stable DWMS production could not be achieved. 
 We fabricated PLG SWMS in DCM to mimic the PLG core of DWMS using a 
double nozzle PPF system. The measured diameter of SWMS, 48.5 µm diameter, was 
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similar to the calculated core diameter of DWMS (Table 4.1). These SWMS were used 
for comparison to the DWMS in BSA in vitro release as well as microscopic study. 
 
Figure 4. 1: Size distributions of DCM(DCM) (A) and EtAc(DCM) (B) DWMS/SWMS: Sample O, (DCM), 
PLA/PLG 0; Sample A1, DCM(DCM), PLA/PLG 1.09; Sample A2, DCM(DCM), PLA/PLG 2.14; Sample 
A3, DCM(DCM), PLA/PLG 3.04; Sample B1, EtAc(DCM), PLA/PLG 1.09; Sample B2, EtAc(DCM), 
PLA/PLG 2.14; Sample B3, EtAc(DCM), PLA/PLG 3.04. 
 
 Initial protein loading and encapsulation efficiency were measured after 
extracting BSA from the particles. The BSA loadings in DWMS of both DCM(DCM) 
and EtAc(DCM) decreased as PLA/PLG mass ratio increased, due to addition of BSA-
free PLA layer. The loadings of BSA in DCM(DCM) DWMS were lower than those in 
EtAc(DCM) DWMS (Figure 4.2A). This may be due to the longer particle hardening 
time of DCM(DCM) DWMS than EtAc(DCM) DWMS, allowing more BSA to escape.  
PLG SWMS exhibited an encapsulation efficiency of 30%, which was close to those of 
DCM(DCM) DWMS of different shell thickness. This meant the drug free PLA shells of 
DCM(DCM) DWMS showed no effect on encapsulation of BSA in the PLG cores. 
However, the encapsulation efficiencies of EtAc(DCM) DWMS with different PLA/PLG 
mass ratio were higher (~50%) than those of DCM(DCM) DWMS (~30%). Surprisingly, 
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the encapsulation efficiency showed no increase with increasing PLA/PLG mass ratio for 
either DCM(DCM) and EtAc(DCM) DWMS (Figure 4.2B).  
 
Figure 4. 2: Loading (A) and encapsulation efficiencies (B) of DWMS with different PLA/PLG mass ratio: 
Sample O, (DCM), PLA/PLG 0; Sample A1, DCM(DCM), PLA/PLG 1.09; Sample A2, DCM(DCM), 
PLA/PLG 2.14; Sample A3, DCM(DCM), PLA/PLG 3.04; Sample B1, EtAc(DCM), PLA/PLG 1.09; 
Sample B2, EtAc(DCM), PLA/PLG 2.14; Sample B3, EtAc(DCM), PLA/PLG 3.04. 
 
4.3.2 BSA In Vitro Release 
BSA cumulative percent release profiles were obtained relative to the initial protein 
loading of DWMS/SWMS (Figure 4.3A, C). The final release amount reached from 
100%-120% of initial loading. This was probably due to under-estimation of the initial 
loading caused by incomplete extraction of BSA. In order to better compare different 
BSA profiles, normalized cumulative fraction release profiles were generated using 
cumulative percent release profiles normalized to final release amount of BSA (Figure 
4.3B, D).  
 BSA release from DWMS with different PLA shell thicknesses were compared 
with the release profile of BSA-loaded PLG SWMS mimicking the PLG cores of DWMS. 
For DCM(DCM) DWMS A1-A3, the profiles of cumulative fraction release of BSA 
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showed a faster initial release in the first 10 days, a lag phase exhibiting slower BSA 
release from ~10-20 days, and a final faster release phase (Figure 4.3A, B). This was also 
the case for BSA release profile of SWMS (O). The initial BSA release rate increased 
with PLA shell thickness because a significant amount of BSA concentrated near the 
surface of DWMS (see Figures 4.4 and 4.5, below). The steady release rates of A1-A3 
after the lag phase were slower than that of O, likely due to the effect of slowly degrading 
PLA shell hindering BSA release from the core, as expected.  
 
Figure 4. 3: In vitro release profiles of BSA from DCM(DCM) DWMS (A), (B) and EtAc(DCM) DWMS 
(C), (D) with different PLA/PLG mass ratio: Sample O, (DCM), PLA/PLG 0; Sample A1, DCM(DCM), 
PLA/PLG 1.09; Sample A2, DCM(DCM), PLA/PLG 2.14; Sample A3, DCM(DCM), PLA/PLG 3.04; 
Sample B1, EtAc(DCM), PLA/PLG 1.09; Sample B2, EtAc(DCM), PLA/PLG 2.14; Sample B3, 
EtAc(DCM), PLA/PLG 3.04. 
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 EtAc(DCM) DWMS B1-B3 exhibited a similar initial release phase with ~35% of 
encapsulated BSA released in the first 10 days (Figure 4.3C, D). The lag phase almost 
merged with steady release phase for DWMS when PLA/PLG mass ratio increased, and 
there was clearly evidence of prolonged BSA release compared to SWMS. For 
EtAc(DCM) DWMS B1 (calculated PLA shell 6.28 µm), the BSA release profile showed 
a longer lag phase from 10 to ~40 days, then an increasing release rate achieving 
complete BSA release at ~90 days. For B2 (calculated PLA shell 10.64 µm), the lag 
phase could not be distinguished from the final steady release phase, and a dramatically 
slower release rate compared to SWMS was observed. Complete BSA release was 
reached at ~120 days. B3 (calculated PLA shell 13.93 µm) exhibited a similar profile 
with even slower release rate through 140 days. Thus, using EtAc(DCM) solvent 
configuration, BSA release was clearly slower and prolonged compared to that of SWMS. 
Upon increasing drug-free PLA shell thickness, BSA in vitro release rates were decreased 
accordingly, as the PLA shells serve as rate-controlling diffusion barrier.  
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Figure 4. 4: Confocal fluorescence micrographs of BSA-loaded SWMS and DWMS: Sample O, (DCM), 
PLA/PLG 0; Sample A1, DCM(DCM), PLA/PLG 1.09; Sample A2, DCM(DCM), PLA/PLG 2.14; Sample 
A3, DCM(DCM), PLA/PLG 3.04; Sample B1, EtAc(DCM), PLA/PLG 1.09; Sample B2, EtAc(DCM), 
PLA/PLG 2.14; Sample B3, EtAc(DCM), PLA/PLG 3.04. 
 
4.3.3 BSA Distribution in DWMS and SWMS 
Confocal fluorescence microscopy allowed visualization of spatial distribution of 
TAMRA-labeled BSA within SWMS and DWMS (Figure 4.4), and image analysis of the 
micrographs provided average radial fluorescence intensities of the particles (Figure 4.5). 
TAMRA-BSA distribution within SWMS (sample O) was relatively uniform across the 
particles. For DCM(DCM) DWMS A1-A3, the TAMRA-BSA fluorescence was 
concentrated in the periphery. As PLA/PLG mass ratio increased, the distance between 
peaks increased accordingly. For the EtAc(DCM) solvent configuration, B1-B3, 
TAMRA-BSA concentrated in the core area and there were clearly drug-free PLA layers 
probably due to the fast extraction rate of EtAc in the shell. The intensity plateau areas 
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are similar for all three shell thicknesses within 25-30 µm of the center, which suggests 
relatively constant BSA-loaded cores and increasing shell thickness. 
 
Figure 4. 5: Average fluorescence intensities of TAMRA-labeled BSA along radial direction of 
microparticles: Sample O, (DCM), PLA/PLG 0; Sample A1, DCM(DCM), PLA/PLG 1.09; Sample A2, 
DCM(DCM), PLA/PLG 2.14; Sample A3, DCM(DCM), PLA/PLG 3.04; Sample B1, EtAc(DCM), 
PLA/PLG 1.09; Sample B2, EtAc(DCM), PLA/PLG 2.14; Sample B3, EtAc(DCM), PLA/PLG 3.04. 
 
4.3.4 DWMS Thermal Properties 
DWMS as well as pure PLA and PLG were examined using DSC to determine the glass 
transition temperature Tg and Tm. For pure PLA and PLG, no Tm was observed within the 
temperature range of 0-200 
o
C, proving these two polymers were amorphous at these 
molecular weights. The Tg peaks of PLA and PLG centered at 50 and 35 
o
C, respectively 
(Figure 4.6).  For DCM(DCM) DWMS A1-A3, the DSC graphs showed combinations of 
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PLA and PLG. The PLG peaks were centered within 30-35 
o
C while the PLA peaks were 
located in the 50-55 
o
C range with even stronger signal than pure PLA (Figure 4.6A). 
These may be caused by the partial mixing of PLG and PLA in these DCM(DCM) 
DWMS. For EtAc(DCM) DWMS B1-B3, the DSC graphs were also combinations of 
pure PLG and PLA, although there were plateaus from 35-50 
o
C and no strong single 
peaks (Figure 4.6B).   
 
Figure 4. 6: DSC graphs of DCM(DCM) DWMS (A), EtAc(DCM) DWMS (B) and pure PLA, PLG. 
 
4.3.5 Surface and Interior Morphology of DWMS and SWMS 
Scanning electron microscopy was employed to study the initial morphology of the 
microparticle surface and interior (Figure 4.7). Micrographs of SWMS mimicking the 
BSA-loaded PLG cores showed coarse surface and porous interior structures (Figure 
4.7O). For DCM(DCM) DWMS, the surfaces were porous and the porosity increased 
with PLA/PLG mass ratio (Figure 4.7A1, A2, A3). Cross-sections showed that porous 
structures concentrated near the particle peripheries especially for high PLA/PLG mass 
ratio. This may be due to the slow removal rate of DCM and the relatively longer particle 
hardening time which causes the BSA-water droplets of the primary emulsion to migrate 
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towards the particle surface or even escape the particles. Relatively low BSA loadings 
and encapsulation efficiencies of DCM(DCM) DWMS agreed with this observation 
(Figure 4.2).  For EtAc(DCM) DWMS, the surfaces were smooth, and cross-section 
micrographs revealed that the porous structures were relatively confined near the core for 
all three PLA/PLG mass ratios (Figure 4.7B1, B2, B3). This was probably due to the 
faster extraction rate of EtAc in the shell phase and fast particle hardening process that 
could better encapsulate the BSA-loaded PLG core. Higher loading and encapsulation 
efficiency of BSA within EtAc(DCM) DWMS agreed with this result. 
 
 
Figure 4. 7: SEM images of DWMS/SWMS: Sample O, (DCM), PLA/PLG 0; Sample A1, DCM(DCM), 
PLA/PLG 1.09; Sample A2, DCM(DCM), PLA/PLG 2.14; Sample A3, DCM(DCM), PLA/PLG 3.04; 
Sample B1, EtAc(DCM), PLA/PLG 1.09; Sample B2, EtAc(DCM), PLA/PLG 2.14; Sample B3, 
EtAc(DCM), PLA/PLG 3.04. 
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4.3. 6 Particle Morphology during In Vitro DWMS Degradation/Erosion 
To correlate initial BSA distribution and release rate profiles with changes in porosity 
and morphology, particles were imaged by SEM at same magnification at various times 
during the release experiment. For DCM(DCM) DWMS A1-A3 (Figure 4.8), most of the 
surface and interior pores were not observed at 21 days. The surfaces became smooth and 
the cross-sections were dense compared to initial state (Figure 4.7). After 42 days, the 
diameters of A1-A3 particles increased, and particle surfaces and interiors became porous 
again, likely due to polymer degradation and erosion. By 63 days, hollow cores began to 
develop, and A1 and A2 (calculated shell thicknesses 6.37 µm and 10.85 µm, 
respectively) broke into pieces while A3 (calculated shell thickness 14.01 µm) remained 
spherical. For (DCM) SWMS O, particles deformed and agglomerated by 21 days and 
quickly broke into pieces after day 42. 
 For EtAc(DCM) DWMS B1-B3 (Figure 4.9), at 21 days, most porous structures 
near the center disappeared, similar to A1-A3. By 42 days, the sizes of B1-B3 DWMS 
had increased, but not as much as A1-A3. From the cross-section micrographs, hollow 
cores began to appear for all three PLA/PLG mass ratios after 42 days. The initial 
porosity of cores in B1-B3 (Figure 4.6) perhaps contributed to their faster erosion. At 63 
days, the surfaces became coarser and the hollow core areas expanded. However, B1-B3 
retained a spherical shape. At day 90, B1 (calculated shell thickness 6.28 µm) broke into 
pieces while B2 (calculated shell thickness 10.64 µm) and B3 (calculated shell thickness 
13.94 µm) remained spherical.   
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Figure 4. 8: SEM images of DCM(DCM) DWMS degradation/erosion study: Sample O, (DCM), PLA/PLG 
0; Sample A1, DCM(DCM), PLA/PLG 1.09; Sample A2, DCM(DCM), PLA/PLG 2.14; Sample A3,  
DCM(DCM), PLA/PLG 3.04. 
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Figure 4. 9: SEM images of EtAc(DCM) DWMS degradation/erosion study: Sample B1, EtAc(DCM), 
PLA/PLG 1.09; Sample B2, EtAc(DCM), PLA/PLG 2.14; Sample B3, EtAc(DCM), PLA/PLG 3.04. 
 
4.3.7 BSA Stability during In Vitro Release 
BSA in supernatants during in vitro release was subjected to SDS-PAGE to study the 
protein stability.  Reducing agents β-mercaptoethanol or DTT in reduced SDS-PAGE can 
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eliminate any covalent protein aggregates, thus, non-reduced condition was chosen for 
this study.  
 From literature, BSA may undergo covalent/non-covalent aggregation as well as 
degradation during matrix degradation/erosion, since BSA may attach to the matrix and 
the microclimate of inner matrix may turn acidic. Non-reduced SDS-PAGE study was 
performed at day 7, 42 and 73 during BSA in vitro release (Figure 4.10). From the gels, 
at day 7, both fresh BSA solution and particle supernatants show strong bands of BSA 
monomer (around 60 kDa) and dimer (around 120 kDa). This proves some BSA 
undergoes aggregation at the initial stage of in vitro release. At Day 42, BSA release 
from SWMS and DWMS showed single bands of BSA monomer, proving most BSA 
retained structural integrity during release. At Day 73, there were no bands observed 
from SWMS sample O as well as DCM(DCM) DWMS sample A1-A3, which was in 
accordance with previous in vitro release study that BSA release was almost finished in 
these samples (Figure 4.3). For EtAc(DCM) DWMS sample B1-B3, BSA monomers 
were still observed.   
 
90 
 
 
Figure 4. 10: SDS-PAGE Gels of BSA in supernatants of SWMS and DWMS at Day 7, 42 and 73. Lane 1: 
protein ladder (10-250 kDa); lane 2: fresh BSA solution; lane 3: BSA from O (SWMS); lane 4-6: BSA from 
A1-A3 (DCM(DCM), DWMS); lane 7-9: BSA from B1-B3 (EtAc(DCM), DWMS)  
 
4.4 Discussion 
The size distribution and structure control of biodegradable microparticles are crucial 
factors for encapsulated protein delivery. Microspheres and double-wall microspheres 
fabricated using conventional methods such as solvent evaporation/extraction usually 
have broad size distributions. Thus the factors influencing protein encapsulation and 
release cannot be easily elucidated. By using precision particle fabrication technique, we 
are able to finely control the diameter as well as the shell thickness of microparticles. 
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This allows us to explore the interconnections between particle structures, initial drug 
distribution and protein release rate.   
 By carefully selecting fabrication parameters such as polymer solution flow rate, 
polymer concentration, and organic solvent configuration, we were able to fabricate 
DWMS with constant core diameter and varying uniform shell thickness. The outer 
diameters of DWMS using either DCM(DCM) or EtAc(DCM) solvent configuration at 
the same flow rates and same PLA/PLG mass ratio were close (within 2 microns, Table 
4.1). However, the surface and cross-section SEM images of DCM(DCM) and 
EtAc(DCM) DWMS showed large differences. Although increasing PLA/PLG mass ratio 
produced an increase of outer diameters in both solvent configurations, the DCM(DCM) 
DWMS A1-A3 surfaces were porous while EtAc(DCM) DWMS B1-B3 surfaces were 
relatively smooth. Besides, the porous structure of DCM(DCM) DWMS were 
concentrated near the periphery while those of EtAc(DCM) DWMS were concentrated in 
the center (Figure 4.7). These differences were probably caused by the 
extraction/evaporation rate difference of DCM and EtAc in the shell phase. The relatively 
fast extraction rate of EtAc in the shell phase better encapsulated BSA-loaded core for all 
three PLA/PLG mass ratios, while for DCM the slow removal rate and longer particle 
hardening time allow the BSA-water droplets to migrate to the particle surfaces.   
 Combining the data of microparticle morphology, initial drug distribution, and in 
vitro release, we found that by using EtAc(DCM), BSA-loaded PLG cores were better 
encapsulated, and the release of BSA was dramatically slower than SWMS without PLA 
shell. Increasing the thickness of PLA drug-free shells postponed BSA release to some 
extent and finally “zero-order” release was achieved. However, for DCM(DCM) DWMS, 
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increasing shell thickness did not slow down BSA release rate due to the redistribution of 
BSA toward the particle surface during fabrication.  
 The in vitro erosion study of DCM(DCM) DWMS showed the relatively even 
distribution of porous structure at early period of degradation and hollow core areas 
began to develop after 63 days (Figure 4.8). The porous structure might be caused by 
BSA-water droplet aggregation, and because of the slow hardening process of 
DCM(DCM) DWMS, these particulates tended to move to the periphery. Since the 
degradation and erosion rates of PLG are much faster than PLA [26], hollow areas 
developed in the core regions. For EtAc(DCM), BSA-water droplets were confined near 
the cores due to the fast EtAc extraction rate, and hollow cores were observed at early 
stage (Figure 4.9).  
 Non-reduced SDS-PAGE was carried out to study the stability of BSA during in 
vitro release. From the gels, BSA undergoes aggregation at the initial stage of in vitro 
release and retains most of its integrity during release.  
4.5 Conclusions 
Monodisperse DWMS with different shell thickness as well as uniform PLG SWMS were 
successfully fabricated using precision particle fabrication. By using EtAc(DCM) solvent 
configuration, DWMS with constant BSA-loaded PLG core and BSA-free PLA shell 
were fabricated with higher BSA loading and encapsulation efficiency. The in vitro 
release profiles of BSA confirmed the hypothesis that increasing shell thickness while 
keeping the protein-loaded core diameter constant postponed the release rate of 
encapsulated protein and “zero-order” release was achieved when PLA/PLG mass ratio 
increased from 1.09 to 3.04.  
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Chapter 5. Uniform Liquid-Core Microcapsules for Protein Delivery 
5.1 Introduction 
Protein therapeutics are being intensively studied in the biotechnology and 
pharmaceutical industries as promising replacements for traditional small-molecule drugs 
due to their unique structure, high pharmacological potency, highly specific functions and 
relatively low side effects [1]. However, since proteins are typically fragile and have very 
short half-lives in vivo, frequent injection or infusion is needed to maintain effective 
protein concentration. The limited administration route of proteins as well as poor control 
of protein delivery rates have become the major obstacles for the wide application of 
protein therapeutics [2]. In response, research in advanced protein delivery systems seeks 
to provide simple, safe and effective methods for administration with advanced control of 
protein concentrations.  
Polymer delivery systems, especially biodegradable polymer microparticles, are a 
popular and promising drug delivery method for small-molecule and macromolecular 
drugs. Polymer microparticles are relatively easy to fabricate, and can be administered 
via simple injection with extended or pulsatile drug release over time periods up to 
several months [3]. By adjusting size distribution as well as structure of microparticles, 
researchers were able to tailor protein release rates as desired [4, 5].  
 Microparticles, such as monolithic microspheres or double-wall microspheres 
composed of two distinct polymers with either core-shell or reservoir structure and drug 
located in one or both of the phases have been fabricated by different research groups for 
advanced protein or drug delivery [6-9]. These particles usually exhibit extended protein 
release rates compared to traditional injection methods. However, there is growing 
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evidence that continuous delivery may not be optimal for all protein drugs, but that 
pulsatile delivery may be preferred in many cases [10-12]. Pulsatile release, which is a 
common phenomenon found in human body, is the rapid release of a certain amount of 
therapeutic during a relatively short time window [13, 14]. This naturally occurring 
mechanism has been mimicked for the development of pulsatile protein release systems 
to improve therapeutic efficacy. For example, a number of hormones are secreted from 
regulatory cells in a pulsatile manner to de- or re-sensitize target cells [15].  
 Researchers have utilized different systems to achieve pulsatile delivery. Methods 
to trigger the pulsatile release include self-degradation/erosion, electric fields, magnetic 
fields, exposure to ultrasound or light, and changes in pH or temperature. For example, 
microparticles blended with magnetic beads exposed to magnetic fields [16], polymer 
microparticles exposed to ultrasound [17], photorupture of polyamide microcapsules [18], 
hydrophobic polyamine copolymer hydrogels with pH changes [19] and sophisticated 
microchip based devices [20] can all generate pulsatile release of encapsulated drugs.  
Among those, liquid-core biodegradable microparticle systems are simple to fabricate 
and do not require an exterior stimulus. With therapeutics loaded within liquid-cores and 
surrounded by biodegradable polymer shells, the particle rupture rate and the drug 
pulsatile release can be controlled by the properties of polymers as well as structure of 
microcapsules [21-23]. However, due to the relatively broad distribution of particle size 
and polymer shell thickness, the pulsatile release profiles are usually irregular and hard to 
control [24]. In this study, we report the first example of uniform microcapsules 
composed of a protein encapsulating liquid-core and uniform poly(lactide-co-glycolide) 
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(PLG) shell as release rate-controlling layer using precision particle fabrication technique 
(PPF) [22, 25]. 
5.2 Materials and Methods 
5.2.1 Materials 
Poly(D,L-lactide-co-glycolide) (PLG, Mw 15 kDa, 38 kDa and 88 kDa; lactide: glycolide 
50:50) were purchased from LACTEL Absorbable Polymers. Chromatography grade 
dichloromethane (DCM) was obtained from Sigma-Aldrich. Bovine serum albumin (BSA, 
Mw 66,700 Da) and dimethyl sulfoxide (DMSO) were purchased from Fisher Scientific. 
Poly(vinyl alcohol) (PVA, Mw 25,000 Da, 88% hydrolyzed) was purchased from 
Polysciences. Tween 80 was purchased from Acros Organics. Canola oil was purchased 
from Spectrum Naturals. 
5.2.2 Liquid-core Microcapsules Fabrication 
The triple nozzle system was employed for producing liquid-core microcapsules using 
PPF (Figure 2.2). For the triple nozzle system, a steel hypodermic needle (PrecisionGlide, 
Becton Dickinson Co.) with flat tip was used as the innermost nozzle, which was 
surrounded coaxially by the inner glass nozzle made from a glass capillary (World 
Precision Instrument, Inc.). The outer glass nozzle surrounded the inner glass nozzle and 
was made of Pyrex glass (Kimax).  
 BSA (100 mg/mL in deionized water) was emulsified with canola oil at a 
volumetric ratio of 1:3, aqueous:organic, by sonication (CE Converter 102 C, Branson)  
in a ice-water bath at 50% amplitude for 1 min with a 15 second interval in the middle  to 
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form the core phase. The shell phase was 10% w/v PLG dissolved in DCM. PVA water 
solution (0.5% w/v) was used as non-solvent carrier stream.  
 
Table 5. 1: PPF parameters for liquid-core microcapsules 
 Liquid-core microcapsules 
Nozzle Configuration Triple Nozzle System 
Shell Flow Rate (mL/h) 30, 40, 50 
Core Flow Rate (mL/h) 1 
Wave Amplitude (V) +5.00 (Maximum) 
Wave Frequency (KHz) 5 
Wave Type Sine 
PVA Flow Rate (mL/h) 500-1100 
 
 The core phase BSA/canola oil emulsion passed through the innermost metal 
nozzle and the shell PLG solution passed through the concentric inner glass nozzle. The 
outermost glass nozzle was for PVA non-solvent carrier stream. The frequency generator 
(Agilent 33220A) and piezoelectric transducer (CV 33, Sonic & Materials Inc.) generated 
an acoustic wave on the nozzle system to break the exiting streams into uniform droplets 
(Figure 2.1A). PPF fabrication parameters of liquid-core microcapsules are shown in 
Table 5.1. Nascent microcapsules were collected in a 500 mL beaker containing 500 mL 
of 0.5% PVA solution and were stirred for 1 h to allow for DCM extraction and 
evaporation. The particles were filtered (Filter Paper #4, Whatman), washed three times 
by deionized water, and lyophilized for 48 h. Samples were stored until use in a -20 
o
C 
freezer with desiccant. 
5.2.3 Particle Size Distribution 
The size distributions of nascent particles (wet particles before lyophilizing) were 
determined using a Coulter Multisizer III (Beckman Coulter Inc.) with a 200 µm aperture 
in Isoton II. More than 5,000 particles were measured for each sample. 
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5.2.4 Initial Core Encapsulation 
Core encapsulation efficiencies (i.e., the percentage of particles exhibiting cores 
completely surrounded by shell PLG) were determined for each microparticle sample 
using light microscopy (Invertoskop, Zeiss). Optical micrographs of several hundred 
microparticles were captured for each sample at the particle midline. Visual observation 
was used to determine the number of particles with fully encapsulated cores relative to 
the total number of particles imaged. All particles exhibiting partial encapsulation, for 
which the core is either protruding from or contacting the exterior wall of the shell, have 
been treated as not encapsulated. 
5.2.5 Protein Loading 
Samples of approximately 10 mg of microcapsules were dissolved in 100 µL DMSO. The 
solution was pipetted into 1 mL of phosphate-buffered saline (PBS, pH 7.4±0.05) then 
incubated for 1 h at 37 
o
C with shaking at 240 rpm. The mixture was centrifuged for 10 
minutes at 10,000 rpm, and BSA concentration in the supernatant was determined using 
BCA assay (Pierce). All absorbance measurements were taken on a SpectraMax 340 PC 
reader equipped with SoFTMax Pro software. The loading equaled the mass of BSA per 
mass of particles. The encapsulation efficiency equaled the actual BSA loading divided 
by theoretical BSA loading multiplied by 100. 
5.2.6 BSA In Vitro Release 
For each batch of microcapsules, a sample of approximately 30 mg was suspended in 
1.25 mL release buffer consisting of 0.05% (v/v) Tween 80 (to prevent particle 
agglomeration) and PBS, pH 7.4. These samples were incubated at 37 
o
C with shaking 
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(240 rpm). At various time points, 1.0 mL supernatant was removed and replaced with 
fresh media in order to maintain constant pH sink condition. Blank microcapsules (same 
fabrication parameters, except no protein was added) were treated the same way and the 
supernatants at various time points were collected as controls. The release study was 
performed in triplicate, and BSA concentrations in the collected supernatants were 
measured using BCA assay (Pierce) with absorbance corrected by absorbance of 
supernatants from blank microcapsules. 
5.2.7 Particle DSC Study 
Differential scanning calorimetry (DSC) was performed on each batch of microcapsules 
as well as pure PLG polymers to study their thermal properties such as glass transition 
temperatures (Tg) and melting temperature (Tm). Perkin Elmer Pyris Diamond DSC was 
used, and all samples were heated from -10 
o
C to 200 
o
C at 10 
o
C/min. 
5.2.8 Scanning Electron Microscopy (SEM) 
Microcapsules were prepared for imaging by placing a droplet of an aqueous particle 
suspension on a silicon stub. The samples were dried overnight and sputter coated with 
gold and platinum prior to imaging. In order to image the cross-sections, microparticles 
were frozen in liquid nitrogen and fractured using a razor blade on a glass slide, 
resuspended in a water droplet, and mounted on silicon stubs. The JEOL 6060 LV 
scanning electron microscope was used at an acceleration voltage of 3-15 kV. 
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5.2.9 Particle Degradation/Erosion Study 
For each batch of microcapsules, a sample of approximately 5 mg was suspended in 1.25 
mL release buffer consisting of 0.05% (v/v) Tween 80 and PBS. These samples were 
incubated at 37 
o
C with shaking (240 rpm). At various time points, all supernatant was 
removed and the samples were frozen and lyophilized for at least 48 h. The samples were 
prepared for SEM as described above. 
5.2.10 SDS-PAGE 
BSA in supernatants during in vitro release was subjected to non-reduced sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis using precast gradient 
gels (4-20% Tris-HCl/glycine) and Mini-PROTEAN II system (Bio-Rad Laboratories, 
Inc.). Running buffer (25 mM Tris, 192 mM glycine and 0.1% (w/v) SDS, pH 8.3) was 
diluted from 10x Tris/Glycine/SDS buffer. Samples were diluted 1:1 in Laemmli sample 
buffer (62.5 mM Tris-HCl, pH 6.8, 25% glycerol, 2% SDS, 0.01% Bromophenol blue) 
under non-reducing conditions (without β-mercaptoethanol or DTT), and heated for 1 
min at 95 
o
C prior to loading. Gels were electrophoresed for 40 min at 200 V and then 
stained with Coomassie blue to visualize the protein bands.  
5.3 Results 
5.3.1 Production of BSA-loaded Microcapsules 
We investigated the effects of PLG molecular weight (15 kDa, 38 kDa and 88 kDa) on 
particle fabrication and BSA encapsulation. In addition, by changing PLG shell phase 
flow rates while keeping the liquid-core phase flow rate constant, we were able to 
fabricate BSA-loaded liquid-core microcapsules with different shell thickness. For each 
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batch of liquid-core microcapsules, we keep all PPF parameters the same except turn off 
the liquid-core phase to fabricate solid PLG microspheres as a size control. Based on the 
measured diameter of microcapsules as well as monolithic microspheres, PLG shell 
thickness can be calculated (Equation (5.1)-(5.3), Table 5.2).  
 Assuming no PLG mass loss during PPF fabrication process, control 
microspheres PLG volumes equal corresponding PLG volumes in microcapsules and 
concentric core-shell structure of microcapsules, core diameter and shell thickness of 
liquid-core microcapsules can be calculated using following equations: 
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         (5.2) 
    
      
 
          (5.3) 
    and    are measured diameter of microcapsules and size control microspheres 
(µm);     and     are the calculated core diameter and shell thickness of liquid-core 
microcapsules (µm). 
 Size distributions of control monolithic microspheres as well as microcapsules are 
shown in Figure 5.1. The calculated liquid core diameter was constant at 45-46 µm, and 
the shell thickness of PLG increased from ~14 µm to ~19 µm upon increasing the PLG 
shell phase flow rate from 30 mL/h to 50 mL/h (Table 5.2).  
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Figure 5. 1: Size distributions of monolithic microspheres A, PLG Mw 15 kDa; C, PLG Mw 38 kDa; E, 
PLG Mw 88 kDa and liquid-core microcapsules B, PLG Mw 15 kDa; D, PLG 38 kDa; F, PLG Mw 88 kDa 
with different PLG phase flow rates (30, 40 and 50 mL/h). 
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Table 5. 2: Dimensions of monolithic microspheres and liquid-core microcapsules 
Sample PLG Mw 
(kDa) 
PLG phase Flow 
Rate (mL/h) 
Outer Diameter 
Measured (µm) 
Core Diameter 
Calculated (µm) 
Shell Thickness 
Calculated (µm) 
microspheres 15 30 68.17 N/A N/A 
microspheres 15 40 72.97 N/A N/A 
microspheres 15 50 78.36 N/A N/A 
microcapsules 15 30 74.82 46.72 14.05 
microcapsules 15 40 78.76 46.43 16.17 
microcapsules 15 50 83.03 45.03 19.00 
microspheres 38 30 66.85 N/A N/A 
microspheres 38 40 73.21 N/A N/A 
microspheres 38 50 78.55 N/A N/A 
microcapsules 38 30 73.40 45.90 13.75 
microcapsules 38 40 78.97 46.44 16.27 
microcapsules 38 50 83.40 45.69 18.85 
microspheres 88 30 68.97 N/A N/A 
microspheres 88 40 74.10 N/A N/A 
microspheres 88 50 79.55 N/A N/A 
microcapsules 88 30 75.07 45.62 14.73 
microcapsules 88 40 79.89 46.89 16.50 
microcapsules 88 50 84.57 46.64 18.96 
 
Table 5. 3: Microcapsules core encapsulation efficiency (%) 
 PLG Flow Rate 30 mL/h PLG Flow Rate 40 mL/h PLG Flow Rate 50 mL/h 
PLG Mw 15 kDa 11 7 4 
PLG Mw 38 kDa 36 49 17 
PLG Mw 88 kDa 97 93 91 
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Figure 5. 2: Light microcopy study of core encapsulation of microcapsules with different PLG Mw (15, 38 
and 88 kDa) and PLG shell flow rates (30, 40 and 50 mL/h), scale bar=50 µm. 
 
5.3.2 Microcapsule Core Encapsulation 
Core encapsulation efficiency was evaluated for each batch of liquid-core microcapsules. 
The light microscope images are shown in Figure 5.2. For lower PLG molecular weight, 
15 kDa, liquid-core encapsulation efficiencies are low (11, 7 and 4%), and most of the 
microparticles exhibit acorn-shape structures with liquid cores protruding at one side. For 
PLG molecular weight 38 kDa, liquid core encapsulation efficiencies are higher (36, 49 
and 17%) compared to molecular weight 15 kDa, but still, the majority of microparticles 
are not fully core-encapsulated. When PLG molecular weight increased to 88 kDa, liquid-
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core encapsulation greatly improved and high core encapsulation efficiencies are 
achieved (97, 93 and 91%). Besides, except microcapsules with PLG molecular weight 
38 kDa, flow rate 40 mL/h, for different PLG molecular weight, core encapsulation 
efficiency decreased with increasing the PLG shell flow rate (Table 5.3).   
5.3.3 Protein Loading and Encapsulation Efficiency of Microcapsules 
 
Figure 5. 3: Loading (A) and encapsulation efficiencies (B) of liquid-core microcapsules with different 
PLG molecular weight (15, 38 and 88 kDa) and PLG shell flow rate (30, 40 and 50 mL/h). 
 
 Initial protein loading and encapsulation efficiency were measured after 
extracting BSA from the particles. The BSA loadings and encapsulation efficiency 
decreased as PLG shell flow rates increased from 30 mL/h to 50 mL/h except for the 
sample with PLG Mw 38 kDa and shell flow rate 40 mL/h, which is in accordance with 
core encapsulation efficiency. For different PLG molecular weight, lower PLG molecular 
weight generated lower loading and encapsulation efficiency. When PLG molecular 
weight increased to 88 kDa, most of the BSA-loaded liquid cores were encapsulated 
within microcapsules (Table 5.3) and the BSA encapsulation efficiencies reached 55-65%. 
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Figure 5. 4: In vitro release profiles of BSA from liquid-core microcapsules of different PLG molecular 
weight ((A), (B), PLG Mw 15 kDa; (C), (D), PLG Mw 38 kDa; (E), (F), PLG Mw 88 kDa) and PLG shell 
flow rate (30, 40 and 50 mL/h). 
 
5.3.4 BSA In Vitro Release 
BSA release profiles were obtained relative to the initial protein loading of liquid-core 
microcapsules (Figure 5.4A, C and E). The final release amount reached 100%-115% of 
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initial loading. This was probably due to under-estimation of the initial loading caused by 
incomplete extraction of BSA from microcapsules. In order to better compare different 
BSA release profiles, normalized cumulative fraction release profiles were generated 
using cumulative percent release profiles normalized to final release amount of BSA 
(Figure 5.4B, D and F). 
 For PLG Mw 15 kDa, the liquid-core encapsulation efficiencies were low, only 4-
11% (Table 5.3), and so were the BSA loading and encapsulation efficiency (Figure 5.3). 
Most of the liquid cores containing BSA were either protruding from one side of the 
particles or attaching on the surface of microparticles. The BSA release rates were very 
fast, and complete BSA release was reached at ~10 days (Figure 5.4A, B).  
 For PLG Mw 38 kDa, with PLG shell flow rates of 30 and 40 mL/h, the liquid-
core encapsulation efficiencies were 36 and 49% respectively. BSA release rates were 
relatively fast from day 1 to day 10, probably due to the microparticles with BSA-
containing liquid cores not fully encapsulated. Subsequently release rates decreased, and 
complete BSA release was observed at ~40 days. For PLG flow rates of 50 mL/h, the 
liquid-core encapsulation efficiency was only 17%, and fast BSA release profile was 
obtained similar to microparticles with PLG Mw 38 kDa with complete BSA release at 
~20 days (Figure 5.4C, D). 
 Microparticles with higher PLG molecular weight (Mw 88 kDa) achieved high 
liquid-core encapsulation efficiencies (91-97%, Table 5.3). We can assume that most of 
the microparticles were liquid-core microcapsules with core-shell structures. The BSA 
release profiles were very different from the ones of microparticles containing lower 
molecular weight PLG. For PLG shell flow rates 30 mL/h (calculated shell thickness 
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14.73 µm, Table 5.2), BSA release rate was slow within ~20 days, and only ~10% of 
BSA encapsulated was released. From day 25 to day 32, a burst release of BSA was 
observed and complete BSA was released at ~32 days. For PLG shell flow rates 40 mL/h 
(calculated shell thickness 16.50 µm, Table 5.2), ~20% of encapsulated BSA was 
released within 32 days, a BSA burst release was observed from ~day 32 to day 40. For 
PLG shell flow rates 50 mL/h (calculated shell thickness 18.96, Table 5.2), similarly, ~25% 
of BSA was slowly released by day 35, followed by a burst release of BSA and complete 
BSA release at day ~42. 
5.3.5 Microcapsules Thermal Properties 
Liquid-core microcapsules as well as pure PLG were examined using DSC to determine 
the glass transition temperature, Tg, and melting point Tm. For pure PLG of varying 
molecular weight (Mw 15, 38 and 88 kDa), no Tm were observed within the temperature 
range of 0-200 
o
C, proving they were all amorphous. The Tg peak of pure PLG Mw 15 
kDa centered at 50 
o
C. For microcapsules with 15 kDa PLG, strongest Tg peaks shifted to 
35 
o
C, probably due to the mixing of canola oil with PLG. There were several minor 
peaks from 130-190 
o
C, probably due to the breakdown of canola oil into glycerol and 
fatty acid. The Tg peak of pure 38 kDa PLG centered at 50 
o
C as well, and microcapsules 
with 38 kDa PLG still centered at 50 
o
C with broader Tg peaks. Minor peaks were also 
observed for microcapsules at 130-190 
o
C. For PLG Mw 88 kDa, pure polymer showed 
strong peaks at 55 
o
C. For microcapsules with 88 kDa PLG, the strongest peaks shifted 
slightly to lower temperature of 45 
o
C, and also Tg peaks became broader probably due to 
canola oil mixing with PLG. Minor peaks due to break down of canola oil also appeared 
from 130-190 
o
C (Figure 5.5). 
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Figure 5. 5: DSC graphs of liquid-core microcapsules of different PLG molecular weight (A), PLG Mw 15 
kDa; (B), PLG Mw 38 kDa; (C), PLG Mw 88 kDa and PLG shell flow rate (30, 40 and 50 mL/h). 
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5.3.6 Surface and Interior Morphology of Microcapsules 
Scanning electron microscopy was employed to study the initial morphology of the 
microparticle surface and interior. For core-shell microcapsules, cross-section 
micrographs were obtained, while for acorn-shape or other liquid-core not fully 
encapsulated microparticles, close-up micrographs were obtained (Figure 5.6).   
 For microcapsules with lower PLG molecular weight (15, 38 kDa), microparticles 
were clearly not spherical, but the solid remainder of the acorn-shape particles was 
observed. For 15 kDa PLG, microparticles have porous structures on the surface for PLG 
shell flow rate 30 mL/h, while increasing PLG shell flow rate to 40 and 50 mL/h, the 
surfaces became relatively smooth. For 38 kDa PLG, wrinkles appeared on the surfaces 
of all microparticles. Upon increasing PLG molecular weight to 88 kDa, microparticles 
became spherical core-shell structure microcapsules. Porous structures and wrinkles 
appeared on the surface of these microcapsules, and the cross-section micrographs 
revealed core-shell structures (Figure 5.6).    
5.3.7 Microcapsules Morphology during In Vitro Degradation/Erosion 
From previous study, we know that only using 88 kDa PLG microparticles showed the 
core-shell structure, pulsatile release profiles and higher core encapsulation efficiency as 
well as BSA loading. To better understand the degradation/erosion of the liquid-core 
microcapsules and to correlate with release profiles of BSA, microcapsules (PLG Mw 88 
kDa, PLG shell flow rate 30, 40 and 50 mL/h) were imaged by SEM at various times 
during the release experiment (Figure 5.7).  
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Figure 5. 6: SEM images of microcapsules of different PLG molecular weight (15, 38 and 88 kDa) and 
PLG shell flow rate (30, 40 and 50 mL/h). 
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Figure 5. 7: SEM images of microcapsules degradation/erosion study with different PLG (Mw 88 kDa) 
shell flow rate (30, 40 and 50 mL/h). 
 
 For microcapsules with PLG shell flow rate 30 mL/h (calculated shell thickness 
14.73 µm), surface porosity increased from day 10 to day 20, and at day 30 
microcapsules collapsed. These results were in accordance with BSA in vitro release 
profile in which BSA exhibited a pulsatile release from day 25 to 32. For microcapsules 
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with PLG flow rates 40 mL/h and 50 mL/h, similarly, surface porosity increased before 
particles broke into pieces between 30 and 40 days. These results also agreed with in 
vitro release profiles in which these two batches of microcapsules showed a pulsatile 
release from ~day 32 to 40 and ~day 35 to 42, respectively.  
5.3.8 BSA Stability during In Vitro Release 
BSA in supernatants during in vitro release was examined using SDS-PAGE to study the 
protein stability. No reducing agent such as β-mercaptoethanol or DTT was used, since 
they can eliminate covalent protein aggregates. From literature, BSA may undergo 
covalent/non-covalent aggregation as well as degradation during matrix 
degradation/erosion, because BSA may attach to the matrix and the microclimate of inner 
matrix may turn acidic. Non-reduced SDS-PAGE study was performed at day 28, 35 and 
39 for 88 kDa microcapsules with PLG shell flow rates of 30, 40 and 50 mL/h 
respectively. From previous in vitro release study, rapid release of BSA was observed 
during this time period. Primarily BSA monomers (around 60 kDa) were observed with 
no severe BSA aggregation or degradation bands revealed (Figure 5.8).  
 
117 
 
 
Figure 5. 8: SDS-PAGE Gel of BSA in supernatants of liquid-core PLG (Mw 88 kDa) microcapsules: Lane 
1: protein ladder (10-250 kDa); lane 2: fresh BSA solution; lane 3: BSA from liquid-core microcapsules 
with PLG shell flow rate 30 mL/h at Day 28; lane 4: BSA from liquid-core microcapsules with PLG shell 
flow rate 40 mL/h at day 35; lane 5: BSA from liquid-core microcapsules with PLG shell flow rate 50 mL/h 
at day 39.  
 
5.4 Discussion 
Besides “zero-order” or constant protein delivery, pulsatile protein delivery is a useful 
and popular release profile that many researchers are trying to achieve. Biodegradable 
microparticle size distribution and structure control are crucial factors for encapsulated 
protein delivery. Through careful parameter selection, we can produce monodisperse 
liquid-core microcapsules with core-shell structure using PPF. The fragile liquid cores 
with encapsulated model protein BSA can be properly confined using biodegradable 
polymer PLG of different molecular weight.  
 Fabrication of liquid-core microcapsules is dependent on polymer solution phase 
(PLG in DCM) fully spreading over the liquid-core phase (emulsion of canola oil and 
BSA water solution). The engulfment is described by spreading coefficient theory as 
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developed by Harkins [26]. Torza and Mason extended Harkin’s theory to systems of two 
immiscible phases suspended in a third immiscible phase [27]. Equation (5.4) allows 
calculation of the spreading coefficient for each phase from the interfacial tensions 
between the phases γ12, γ23 and γ13.  
                                (5.4) 
Since γij=γji, there are only three independent spreading coefficients defining the system, 
and these can be referred to by their first subscript: 
                
                                               (5.5)
                                      
                                                    √   √   
                     (5.6) 
Assuming phase 2 is the suspending PVA phase and phase 1 (liquid core) is specified to 
be such that γ12>γ32 (i.e. λ1<0), it is found that only three possible scenarios exist for the 
values of the spreading coefficients in Table 5.4. Case A is total engulfment of liquid 
core by PLG solution phase (phase 3), Case B is partial engulfment, and Case C is no 
engulfment (Figure 5.9). By Harkins’ definition, a positive spreading coefficient leads to 
spreading. In Case A, total engulfment will occur since λ3 is positive, i.e. PLG phase 
wants to spread on liquid core. For Case B, since all spreading coefficients are negative, 
none of the phases wants to spread on any of the others, and a three component line 
interface results (acorn-shape structure). When spreading coefficient 1 and 3 are negative 
but 2 is positive, a separate phase system is present. In this case the solvent PVA wants to 
spread around both liquid core and PLG shell.  
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 Interfacial tension is commonly approximated from Equation (5.6) [28], and for 
PLG, PVA and liquid-core emulsion, the exact γi is unknown. Since polymer interfacial 
tension increases with molecular weight [29], interfacial tension of PLG phase and PVA 
phase (γ32) as well as interfacial tension of PLG phase and liquid core phase (γ31) can 
either increase (if √    √  , √    √  ) or decrease (if √   √  , √    √  ). 
Thus the sum of γ31+γ32 can also increase or decrease with increasing PLG molecular 
weight. For lower PLG molecular weight (15, 38 kDa), acorn-shape microparticles 
comprised a large percentage of the particles, so Case B occurred and            
                 <0.  Thus,             (i.e. interfacial tension of liquid-core 
phase and PVA is smaller than the sum of interfacial tension of PLG solution with two 
other phases). Increasing PLG molecular weight to 88 kDa, most microparticles are core-
shell structure microcapsules, so Case A occurred and                    
         >0, thus             (i.e. interfacial tension of liquid-core phase and 
PVA is bigger than the sum of interfacial tension of PLG with two other phases).  
Table 5. 4: Prediction of final configuration based on spreading coefficients 
Case A Case B Case C 
λ1<0 λ1<0 λ1<0 
λ2<0 λ2<0 λ2>0 
λ3>0 λ3<0 λ3<0 
 
 
Figure 5. 9: Schematic of possible liquid phase (hydrophobic) and PLG phase spreading configurations: (A) 
total engulfment (core-shell microcapsules), (B) partial encapsulation (acorn-shape) and (C) no engulfment.   
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 The light microscopy as well as BSA loading and encapsulation efficiency test 
confirmed that when the PLG fully encapsulated the liquid-core forming the core-shell 
structure, microparticles had high BSA loading and encapsulation efficiency. From BSA 
in vitro release profiles, we noticed that only microcapsules with core-shell structure 
would generate BSA pulsatile or burst release after microparticles were incubated for 
several weeks.  In addition, with increasing PLG shell flow rates and, thus, increasing 
PLG shell thickness while keeping the liquid-core constant, the starting time of pulsatile 
release was delayed. 
 SEM was used to study the initial microparticle morphology and microcapsule 
morphology during in vitro degradation. For 88 kDa PLG microcapsules, core-shell 
structures were observed throughout degradation until microcapsules’ collapse. For the 
surfaces, porous structure appeared, and the surface became more porous and 
microcapsules gradually lost spherical shape during degradation. The pulsatile release 
profiles correlated with the rupture time of microcapsules. Throughout degradation, the 
porous structures probably caused by PLG degradation developed in the PLG shell until 
microcapsules’ rupture and most BSA was released within a short time frame.  
5.5 Conclusions 
Uniform liquid-core microcapsules with different shell thickness were successfully 
fabricated using precision particle fabrication by keeping the liquid-core phase flow rate 
constant while gradually increasing PLG shell flow rate (30 mL/h, 40 mL/h and 50 mL/h). 
By using higher molecular weight PLG (88 kDa), most microparticles exhibited core-
shell structure, and BSA loading and encapsulation efficiency were high. The in vitro 
release profiles of BSA confirmed the hypothesis that BSA pulsatile release could be 
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achieved using liquid-core microcapsules, and increasing microcapsules shell thickness 
while keeping the protein-loaded liquid core diameter constant postponed the starting 
time of pulsatile release.   
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Chapter 6. Perspectives of Current Project and Future Works  
Polymeric microparticles have shown great promise for the delivery of therapeutic 
proteins, due to their compatibility, ease of administration, and capability for 
sustained/pulsatile release. Nevertheless, there are still some major obstacles such as 
protein stability and depot safety during release. In the past few years, researchers have 
achieved exciting progress for polymeric delivery devices to effectively deliver protein 
therapeutics in vitro and in vivo in a controlled manner.  
6.1 Protein Delivery Issues 
In this project, by using Precision Particle Fabrication technology, we were able to 
fabricate monodisperse double-wall microspheres and microcapsules with finely 
controlled overall diameter and shell thickness. The release profiles of model protein 
bovine serum albumin (BSA) from these microparticles showed promising results of 
extended constant release and pulsatile release. However, loss of protein stability and 
bioactivity has been identified as an important limitation by researchers from different 
laboratories especially for long-term protein delivery [1-3]. Protein therapeutics may 
undergo reversible structure changes in performing their biological functions and they 
may lose their structural properties during depot fabrication, injection and drug release 
process. Because we employed a relatively robust and stable albumin as the model 
protein in this thesis, these problems may not have been fully elucidated. The acidic 
microenvironment generated within most polyester matrices during degradation as well 
as other deleterious conditions such as high temperature and shear forces encountered 
during particle fabrication may strongly affect the stability of fragile protein therapeutics. 
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Besides, since protein properties such as molecular weight, solubility, charge and 
conformation differ a lot, therapeutic proteins with real efficacy may exhibit special 
properties during depot fabrication and drug administration such as tendencies to 
aggregate in concentrated formulations and denature at high temperature, low pH or upon 
exposure to organic solvent. These may require special efforts in adapting PPF to 
fabricate drug-containing depots. For example, using diluted protein solution or using 
solid protein powder suspended in polymer matrix; increasing protein activity by 
PEGylation [4], construction of dimeric proteins [5-7] or glycoengineering [8]; keeping 
the protein containing tubing, nozzle system and collecting system at low temperature; 
adding alkaline excipient in polymer matrix; decreasing the exposure of organic solvent 
when loading proteins; or choosing solvents that are less deleterious to protein structure.  
Since PPF is a modified solvent extraction/evaporation method operated at room 
temperature, organic solvents are involved in matrix fabrication process, and temperature 
control is poor. To improve protein stability, better temperature control and new protein 
loading methods with less exposure to organic solvent should be employed such as 
operating PPF at low temperature and collecting samples in ice-water bath. Also, instead 
of first preparing protein-loaded polymer-drug mixture and then fabricating 
microparticles, we can fabricate blank polymer microparticles first.  After the organic 
solvent is removed from the matrix, protein drugs are then loaded into the microparticles 
using novel methods such as “active self-healing” mechanism [9, 10]. Because PPF can 
produce microparticles with narrow size distribution, particle properties are relatively 
uniform. Thus, special efforts in matrix modification can have effective impact on the 
stability of protein encapsulated. Currently, there are no standard experimental conditions 
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or no standard formulations that can be used for all different types of proteins. 
Differences in protein properties make each protein therapeutic unique, so that specific 
formulations are required [11].   
6.2 Depot Safety Issues 
As a modified solvent extraction method, PPF involves using organic solvent such as 
dichloromethane, ethyl acetate or acetonitrile. Although solvent extraction/evaporation 
and particle lyophilization can eliminate most of the residual organic solvent, for safety 
reason, strict monitoring of organic solvent residue may be needed. These analyses can 
increase the cost of depot fabrication. In industry, companies are exploring other new 
fabrication technologies such as hot melt extrusion (HME) to replace solvent extraction 
methods [12]. At Orbis Biosciences, for example, scientists are adapting PPF to hot melt 
extrusion technique. Polymers are melted with therapeutics at high temperature, and 
without using organic solvent, drug-loaded depots can be fabricated with narrow size 
distributions. Although HME is gaining popularity in the pharmaceutical industry, it is 
unlikely to be applicable for fragile macromolecules such as protein and DNA due to the 
high process temperature. So there is still strong demand for new depot fabrication 
technology or improvement of existing methods to produce protein-loaded depot. For 
example, injection/compression molding is one promising solvent-free depot fabrication 
method operated at low temperature [13].  
6.3 Current Perspectives 
By studying the encapsulation and release of model protein BSA from uniform double-
wall microspheres and liquid-core microcapsules with different polymer, solvent and 
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structural properties, we can conclude several general guidelines for protein drug delivery 
using biodegradable microparticles:  
1. Solvents leading to fast particle hardening are better in constraining protein drugs 
within microparticles 
2. Proper initial protein distribution (after particle hardening) is crucial for achieving 
desired release rate 
3. Hydrophilic polymers tend to better encapsulate protein-water particulates than 
hydrophobic polymers 
4. Polymer molecular weight and morphology determine polymer matrix 
degradation rate and protein release profile 
5. Drug-free polymer shell with varied thickness can postpone protein release rate to 
certain extent  
6.4 Future Works 
Using double-wall microspheres as well as liquid-core microcapsules, we are able to 
finely control the release rates of model protein BSA by controlling particle diameter and 
drug-free shell thickness. However, the protein loadings (~1%) are still relatively low 
compared to other monolithic microsphere depots. Our future goals include exploring 
different polymers, solvent combinations and geometric structures such as overall particle 
diameter and shell thickness to optimize protein loading, so that precious protein 
therapeutics can be saved.  
 For biodegradable polymers, although PLG- and PLA-based polymer depots are 
FDA approved, there are still some other choices, such as using surface eroding polymers 
or natural polymers. The polymer configuration of double-wall microsphere can also be 
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optimized to meet specific protein requirement. For example, changing core/shell 
polymer molecular weight, thus changing their hydrophobicity/hydrophilicity, protein 
water-emulsion preferential encapsulation may be achieved. Besides, for liquid-core 
microcapsules, protein emulsion method is still used to encapsulate protein drugs. 
Although emulsion methods can evenly distribute the protein drugs within the particles, 
there is high probability that protein might have contact with the organic solvent which is 
used to dissolve the shell polymer. This may lead to protein denaturation or loss of 
bioactivity. Encapsulating protein as a solid suspension of lyophilized powder within an 
oil core may be a promising way to solve this problem, although one might encounter 
difficulty in even distribution of solid powder within viscous oil.  
 The microparticle formulation and in vitro release profiles of this project can 
provide general guidance for designing biodegradable microscale protein delivery 
vehicles. However, in vivo study of formulations to deliver specific protein therapeutics is 
still needed before clinical test. The PPF technology can eliminate size factors of 
microparticles, enabling us to focus on other factors/methods such as polymer/protein 
properties, surface modification, or particle geometric structure to improve protein 
encapsulation efficiency, achieve targeted delivery and desired protein release profiles. 
For targeted delivery of microparticles to specific tissue or organ, we can modify the 
surface of microparticles of desired diameter with special ligands. By loading two 
different therapeutic proteins at the core and shell phase of DWMS as well as liquid-core 
microcapsules, tandem or simultaneous release of two proteins may be achieved.  
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